POLYNUCLEOTIDE CONSTRUCTS HAVING AN AUXILIARY MOIETY NON-BIOREVERSIBLY LINKED TO AN INTERNUCLEOSIDE PHOSPHATE OR PHOSPHOROTHIOATE

Abstract

The invention features a hybridized polynucleotide construct including a passenger strand, a guide strand loadable into a RISC complex, and one or more auxiliary moieties. At least one of the auxiliary moieties is non-bioreversibly linked to an internucleoside phosphate or phosphorothioate in the passenger strand. The invention further features methods of delivery a polynucleotide construct to a cell and methods of reducing the expression of a protein in a cell. The methods typically involve contacting the cell with the hybridized polynucleotide construct.

Claims

1. A hybridized polynucleotide construct comprising a passenger strand, a guide strand loadable into a RISC complex, and one or more auxiliary moieties; wherein at least one of said auxiliary moieties is non-bioreversibly linked to an internucleoside phosphate or phosphorothioate in said passenger strand; wherein said auxiliary moieties are independently selected from the group consisting of a targeting moiety, a cell penetrating peptide, an endosomal escape moiety, and a neutral organic polymer.

2. The hybridized polynucleotide construct of claim 1, comprising 5 or fewer auxiliary moieties, at least one of said auxiliary moieties being linked non-bioreversibly to an internucleoside phosphate or phosphorothioate in said passenger strand, and the remaining of said auxiliary moieties being independently linked bioreversibly to a phosphate or phosphorothioate in said guide strand or linked bioreversibly or non-bioreversibly to a phosphate or phosphorothioate in said passenger strand.

3. The hybridized polynucleotide construct of claim 1, wherein said passenger strand comprises a pattern N-p.sup.L-(N-p-).sub.z-N-p.sup.L-(N-p-).sub.z-N-p.sup.L-[(N-p-).sub.z-N-p.sup.L-].sub.z1-, wherein each N is independently a nucleoside; each p.sup.L is a phosphate or phosphorothioate linked non-bioreversibly to an auxiliary moiety; each p is independently a phosphate, phosphorothioate, phosphoramidate, or phosphonate; each z is independently 0, 1, or 2; and z1 is 0, 1, or 2.

4. The hybridized polynucleotide construct of claim 1, wherein said auxiliary moieties are the same.

5. The hybridized polynucleotide construct of claim 1, wherein said auxiliary moieties are linked to proximal phosphates or phosphorothioates.

6. The hybridized polynucleotide construct of claim 1, wherein each of said auxiliary moieties is a targeting moiety comprising a single ligand.

7. The hybridized polynucleotide construct of claim 6, wherein said ligand is linked to said internucleoside phosphate or phosphorothioate through a linear oligomeric linker.

8. The hybridized polynucleotide construct of claim 7, wherein said linear oligomeric linker comprises poly(ethylene glycol).

9. The hybridized polynucleotide of claim 1, wherein said hybridized polynucleotide comprises at least two auxiliary moieties linked to phosphates or phosphorothioates in said guide strand or said passenger strand.

10. (canceled)

11. (canceled)

12. (canceled)

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. The hybridized polynucleotide construct of claim 1, wherein said guide strand comprises at least one internucleoside phosphorothioate linking two of the four 3-terminal nucleosides in said guide strand; said guide strand comprises at least one internucleoside phosphorothioate linking two of the four 5-terminal nucleosides in said guide strand; and/or said passenger strand comprises at least one internucleoside phosphorothioate linking two of the four 5-terminal nucleosides in said passenger strand.

18. (canceled)

19. (canceled)

20. The hybridized polynucleotide construct of claim 1, wherein said auxiliary moiety is non-bioreversibly linked through a non-bioreversible linker comprising a 1,2,3-triazole, a N-sulfonylamidocarbonyl, or an amide.

21. The hybridized polynucleotide construct of claim 20, wherein said auxiliary moiety combines with said non-bioreversible linker to form a group that is ##STR00092## wherein R is said auxiliary moiety; R.sup.B is H or C.sub.1-6 alkyl; and L is C.sub.2-6 alkylene or (CH.sub.2CH.sub.2O).sub.p1(CH.sub.2CH.sub.2), wherein p1 is an integer from 1 to 50.

22. The hybridized polynucleotide construct of claim 1, wherein at least one of said auxiliary moieties is a targeting moiety.

23. The hybridized polynucleotide construct of claim 22, wherein said targeting moiety comprises a ligand that is N-acetyl galactosamine, mannose, folate, prostate specific membrane antigen (PSMA), or an antibody or an antigen-binding fragment thereof.

24. The hybridized polynucleotide construct of claim 23, wherein said targeting moiety comprises a ligand that is N-acetyl galactosamine linked to said phosphate or phosphorothioate through a linker bonded to the anomeric carbon of N-acetyl galactosamine, wherein said anomeric carbon is part of a hemiaminal group.

25. (canceled)

26. (canceled)

27. (canceled)

28. The hybridized polynucleotide construct of claim 1, wherein said guide strand or said passenger strand further comprises one or more internucleoside phosphotriesters, internucleoside phosphonates, or internucleoside phosphoramidates.

29. The hybridized polynucleotide construct of claim 28, wherein said guide strand or said passenger strand comprises one or more of said internucleoside phosphotriesters, wherein at least one of said internucleoside phosphotriesters is a non-bioreversible phosphotriester.

30. The hybridized polynucleotide construct of claim 29, wherein each of said non-bioreversible phosphotriesters is a phosphate or a phosphorothioate substituted with a substituent selected independently from the group consisting of optionally substituted C.sub.2-16 alkyl; optionally substituted C.sub.3-16 alkenyl; optionally substituted C.sub.3-16 alkynyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted C.sub.3-8 cycloalkenyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted (C.sub.3-8 cycloalkenyl)-C.sub.1-4-alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from N, O, and S, wherein said heterocyclyl does not comprise an SS bond; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S, wherein said heterocyclyl does not comprise an SS bond; and a group of the following structure: ##STR00093## wherein L is optionally substituted C.sub.2-16 alkylene; R.sup.A is optionally substituted C.sub.2-6 alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from the group consisting of N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from the group consisting of N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from the group consisting of N, O, and S, wherein said heterocyclyl does not comprise an SS bond; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S, wherein said heterocyclyl does not comprise an SS bond; and a poly(ethylene glycol) terminated with OH, C.sub.1-6 alkoxy, or COOH; and R.sup.B is H or optionally substituted C.sub.1-6 alkyl.

31. The hybridized polynucleotide construct of claim 29, wherein each of said non-bioreversible phosphotriesters is a phosphate or a phosphorothioate substituted with a substituent that is ##STR00094## or a group formed by cycloaddition reaction of ##STR00095## with an azido-containing substrate, wherein n is an integer from 1 to 6; n1 is an integer from 1 to 6; R.sup.C is optionally substituted C.sub.6 aryl; optionally substituted C.sub.4-5 heteroaryl that is a six member ring comprising 1 or 2 nitrogen atoms; or optionally substituted C.sub.4-5 heterocyclyl that is a six member ring comprising 1 or 2 nitrogen atoms; R.sup.D is H or 01-6 alkyl; each R.sup.D1 is independently H or C.sub.1-6 alkyl, provided that ##STR00096## contains 24 carbon atoms or fewer; X is a halogen, COOR.sup.1, or CONR.sup.2.sub.2, wherein each of R.sup.1 and R.sup.2 is independently H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.6-14 aryl, optionally substituted C.sub.1-9 heteroaryl, or optionally substituted C.sub.2-9 heterocyclyl; and said azido-containing substrate is ##STR00097##

32. The hybridized polynucleotide construct of claim 28, wherein said guide strand comprises from 1 to 5 of said non-bioreversible phosphotriesters.

33. The hybridized polynucleotide construct of claim 28, wherein one of said non-bioreversible phosphotriesters connects the second nucleoside and the third nucleoside of said guide strand; one of said non-bioreversible phosphotriesters connects the fifth nucleoside and the sixth nucleoside of said guide strand; one of said non-bioreversible phosphotriesters connects the seventeenth nucleoside and the eighteenth nucleoside of said guide strand; one of said non-bioreversible phosphotriesters connects the nineteenth nucleoside and the twentieth nucleoside of said guide strand; and/or one of said non-bioreversible phosphotriesters connects the twentieth nucleoside and the twenty first nucleoside of said guide strand.

34. (canceled)

35. (canceled)

36. (canceled)

37. (canceled)

38. The hybridized polynucleotide construct of claim 28, wherein said passenger strand comprises from 1 to 5 of said non-bioreversible phosphotriesters.

39. The hybridized polynucleotide construct of claim 28, wherein said guide strand or said passenger strand comprises one or more of said internucleoside phosphotriesters, at least one of said internucleoside phosphotriesters being a bioreversible phosphotriester.

40. The hybridized polynucleotide construct of claim 39, wherein said bioreversible phosphotriester is a phosphate or a phosphorothioate substituted with -(Link A)-SSR.sup.E, wherein Link A is a divalent or trivalent linker comprising an sp.sup.3-hybridized carbon atom bonded to said phosphate or phosphorothioate and a carbon atom bonded to SS, wherein, when Link A is a trivalent linker, the third valency of Link A combines with SS and R.sup.E to form optionally substituted C.sub.3-9 heterocyclylene, and R.sup.E is optionally substituted C.sub.2-8 alkyl; optionally substituted C.sub.3-8 alkenyl; optionally substituted C.sub.3-8 alkynyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted C.sub.3-8 cycloalkenyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted (C.sub.3-8 cycloalkenyl)-C.sub.1-4-alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; or, when Link A is a trivalent linker, R.sup.E combines with SS and Link A to form optionally substituted C.sub.3-9 heterocyclylene.

41. The hybridized polynucleotide construct of claim 40, wherein said bioreversible phosphotriester is a phosphate or a phosphorothioate substituted with a group that is ##STR00098## wherein R.sup.F is optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-14 aryl, R.sup.G is a halogen or optionally substituted C.sub.1-6 alkyl, and q is an integer from 0 to 4.

42. The hybridized polynucleotide construct of claim 39, wherein q is 0 and R.sup.F is optionally substituted C.sub.1-6 alkyl.

43. The hybridized polynucleotide construct of claim 28, wherein said guide strand or said passenger strand comprises one or more phosphonates.

44. The hybridized polynucleotide construct of claim 1, wherein said guide strand comprises 19 or more nucleosides.

45. The hybridized polynucleotide construct of claim 1, wherein said guide strand comprises fewer than 100 nucleosides.

46. (canceled)

47. (canceled)

48. The hybridized polynucleotide construct of claim 1, wherein said passenger strand comprises 19 or more nucleosides.

49. The hybridized polynucleotide construct of claim 1, wherein said passenger strand comprises fewer than 100 nucleosides.

50. (canceled)

51. (canceled)

52. A method of delivering a polynucleotide construct to a cell comprising contacting said cell with the hybridized polynucleotide construct of claim 1, wherein, after said contacting, said polynucleotide construct resides inside said cell.

53. A method of reducing the expression of a protein in a cell comprising contacting said cell with the hybridized polynucleotide construct of claim 1, wherein, after said contacting, expression of said protein in said cell is reduced.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0144] FIG. 1 is a chart showing structures of certain phosphotriesters.

[0145] FIG. 2 is an image of a gel showing the serum stability of the hybridized polynucleotide constructs including phosphotriesters relative to that of the hybridized polynucleotide constructs lacking phosphotriesters.

[0146] FIGS. 3-15 are graphs showing AT3 gene expression levels over time in vivo after 0.5 mg/kg dosing with a hybridized polynucleotide constructs or with saline.

DETAILED DESCRIPTION

[0147] The invention provides a hybridized polynucleotide construct containing a passenger strand, a guide strand loadable into a RISC complex, and one or more auxiliary moieties described herein (e.g., from 1 to 5 or from 1 to 3 auxiliary moieties) linked to a phosphate or a phosphorothioate in the passenger strand or the guide strand. At least one (e.g., all) of the auxiliary moieties may be non-bioreversibly linked to a phosphate or phosphorothioate (e.g., an internucleoside phosphate or phosphorothioate) in the passenger strand. The hybridized polynucleotide construct may include one or more auxiliary moieties (e.g., from 1 to 3 auxiliary moieties) bioreversibly linked to a phosphate or phosphorothioate (e.g., an internucleoside phosphate or phosphorothioate) in the passenger strand. The hybridized polynucleotide construct may include one or more auxiliary moieties (e.g., from 1 to 3 auxiliary moieties) bioreversibly linked to a phosphate or phosphorothioate (e.g., an internucleoside phosphate or phosphorothioate) in the guide strand. In some embodiments, the auxiliary moieties in the hybridized polynucleotide construct are linked to the passenger strand. At least some of the auxiliary moieties may be linked to internucleoside phosphates or phosphorothioates in the following pattern: N-p.sup.L-(N-p-).sub.z-N-p.sup.L-(N-p-).sub.z-N-p.sup.L-[(N-p-).sub.z-N-p.sup.L-].sub.z1-, where each N is independently a nucleoside; each p.sup.L is a phosphate or phosphorothioate linked (e.g., non-bioreversibly) to an auxiliary moiety; each p is independently a phosphate, phosphorothioate, phosphoramidate, or phosphonate; each z is independently 0, 1, or 2; and z1 is 0, 1, or 2.

[0148] Typically, the hybridized polynucleotide constructs disclosed herein include one or more internucleoside phosphotriesters, internucleoside phosphonates, or internucleoside phosphorothioates connecting two or more of the five contiguous 5-terminal nucleosides (e.g., in the guide strand or in the passenger strand) and the five contiguous 3-terminal nucleosides (e.g., in the guide strand or in the passenger strand). Certain hybridized polynucleotide constructs include one or more internucleoside phosphotriesters, internucleoside phosphonates, or internucleoside phosphorothioates connecting two or more of the five contiguous 5-terminal nucleosides in the passenger strand, the five contiguous 3-terminal nucleosides in the passenger strand, the five contiguous 5-terminal nucleosides in the guide strand, and the five contiguous 3-terminal nucleosides in the guide strand.

[0149] The hybridized polynucleotide construct may include at least one (e.g., 1, 2, or 3) internucleoside phosphorothioates, each of the internucleoside phosphorothioates linking two contiguous nucleosides of the four 3-terminal nucleosides in the guide strand. The hybridized polynucleotide construct may include at least one (e.g., 1, 2, or 3) internucleoside phosphorothioates, each of the internucleoside phosphorothioates linking two contiguous nucleosides of the four 5-terminal nucleosides in the guide strand. The hybridized polynucleotide construct may include at least one (e.g., 1, 2, or 3) internucleoside phosphorothioates, each of the internucleoside phosphorothioates linking two contiguous nucleosides of the four 3-terminal nucleosides in the passenger strand. The hybridized polynucleotide construct may include at least one (e.g., 1, 2, or 3) internucleoside phosphorothioates, each of the internucleoside phosphorothioates linking two contiguous nucleosides of the four 5-terminal nucleosides in the passenger strand.

[0150] In some embodiments, each of the passenger strand and the guide strand may independently have the structure of the following formula:

[0151] 5-D-(Nuc-E).sub.n-Nuc-F, or a salt thereof,

[0152] where

[0153] each n is independently an integer from 10 to 150 (e.g., from 14 to 99, from 18 to 49, or from 18 to 31),

[0154] each Nuc is independently a nucleoside; and

[0155] D of the guide strand is hydroxyl, phosphate, phosphorothioate, or a bioreversible linker bonded to an auxiliary moiety (e.g., a linker containing phosphate or phosphorothioate bonded to Nuc);

[0156] D of the passenger strand is H, hydroxyl, optionally substituted C.sub.1-6 alkoxy, a protected hydroxyl group, phosphate optionally substituted with C.sub.3-8 alkynyl, phosphorothioate optionally substituted with C.sub.3-8 alkynyl, diphosphate, triphosphate, tetraphosphate, pentaphosphate, a 5 cap, an optionally substituted C.sub.1-6 alkyl, a biotin containing group, a digoxigenin containing group, a cholesterol containing group, a dye containing group, a quencher containing group, or a non-bioreversible or bioreversible linker bonded to an auxiliary moiety (e.g., a linker containing a phosphate or a phosphorothioate bonded to Nuc);

[0157] each E of the passenger strand is independently a phosphate, a phosphorothioate, a phosphoramidate, or a phosphonate, where, optionally, the phosphate or the phosphorothioate is bioreversibly or non-bioreversibly linked to an auxiliary moiety;

[0158] each E of the guide strand is independently a phosphate, a phosphorothioate, or a phosphonate, where, optionally, the phosphate or the phosphorothioate is bioreversibly linked to an auxiliary moiety;

[0159] each F is independently H, hydroxyl, optionally substituted C.sub.1-6 alkoxy, a protected hydroxyl group, phosphate optionally substituted with C.sub.3-8 alkynyl, phosphorothioate optionally substituted with C.sub.3-8 alkynyl, diphosphate, triphosphate, tetraphosphate, pentaphosphate, an optionally substituted C.sub.1-6 alkyl, a biotin containing group, a digoxigenin containing group, a dye containing group, a quencher containing group, or a non-bioreversible or bioreversible linker bonded to an auxiliary moiety (e.g., a linker containing a phosphate or a phosphorothioate bonded to Nuc). At least one E is the phosphate or phosphorothioate non-bioreversibly linked to the auxiliary moiety.

[0160] The auxiliary moiety may be a targeting moiety. The targeting moieties having a single ligand are advantageous when multiple (e.g., 3) targeting moieties (e.g., multiple copies of the same targeting moiety) are proximally disposed within the polynucleotide constructs. Such polynucleotide constructs may exhibit prolonged activity relatively to polynucleotide constructs having the same number of ligands disposed within a single targeting moiety. For example, FIG. 11 shows that SB-0932 (SEQ ID NOs.: 25 and 6), which includes three monomeric auxiliary moieties proximally disposed within the passenger strand, exhibits prolonged and potent activity relatively to SB-0206 (SEQ ID NOs.: 3 and 4) and SB-0887 (SEQ ID NOs.: 10 and 6), each of which includes a single trimeric auxiliary moiety (also see Table 4).

[0161] The hybridized polynucleotide construct may include a guide strand having 19 or more nucleosides. The guide strand may have fewer than 100 nucleosides (e.g., fewer than 50 nucleosides or fewer than 32 nucleosides). The hybridized polynucleotide construct may include a passenger strand having 19 or more nucleosides. The passenger strand may have fewer than 100 nucleosides (e.g., fewer than 50 nucleosides or fewer than 32 nucleosides). Preferably each of the passenger and guide strand will independently include from 19 to 50 nucleosides (e.g., from 19 to 32 nucleoside). The passenger and guide strands can be complimentary to each other over at least 12 contiguous nucleosides (e.g., over at least 15 contiguous nucleosides).

[0162] In addition to the moieties described above, the hybridized polynucleotide construct may contain one or more of non-bioreversible phosphotriesters, bioreversible phosphotriesters, phosphoramidates, and phosphonates.

[0163] The 5- or 3-terminus or both termini of the passenger strand may include non-bioreversible phosphodiesters, which differ from non-bioreversible phosphotriesters described herein only in that the phosphodiester includes OH or O (e.g., a salt) bonded to the phosphorus atom of the phosphodiester.

[0164] The 5- or 3-terminus or both termini of the passenger strand may include bioreversible phosphodiesters, which differ from bioreversible phosphotriesters described herein only in that the phosphodiester includes OH or O (e.g., a salt) bonded to the phosphorus atom of the phosphodiester. The 5- or 3-terminus or both termini of the guide strand may include non-bioreversible phosphodiesters, which differ from non-bioreversible phosphotriesters described herein only in that the phosphodiester includes OH or O (e.g., a salt) bonded to the phosphorus atom of the phosphodiester. The 5- or 3-terminus or both termini of the guide strand may include bioreversible phosphodiesters, which differ from bioreversible phosphotriesters described herein only in that the phosphodiester includes OH or O (e.g., a salt) bonded to the phosphorus atom of the phosphodiester.

[0165] The hybridized polynucleotide construct may further include a second passenger strand and optionally a second guide strand. The second passenger strand may be bioreversibly linked to the first passenger strand of the hybridized polynucleotide construct. The second guide strand, when present, may be hybridized to the second passenger strand.

[0166] Any nucleic acid, regardless of sequence composition, can be modified. Accordingly, the invention is not limited to any particular sequence (e.g., any particular siRNA). Also, polynucleotide constructs disclosed in WO 2015/069932 and in WO 2015/188197 may be modified to include auxiliary moieties as described herein; the disclosure of polynucleotide constructs disclosed in WO 2015/069932 and in WO 2015/188197 is incorporated herein by reference.

[0167] These hybridized polynucleotide constructs may exhibit a superior efficacy in gene silencing relative the hybridized polynucleotide constructs that differ only by the absence of the internucleoside phosphate or phosphorothioate that is non-bioreversibly linked to an auxiliary moiety. Without being bound by theory, the superior efficacy may be due to an improvement in the kinetics of the RISC complex loading or an improvement in the stability of the hybridized polynucleotide construct.

[0168] The invention provides compositions and methods to facilitate and improve the cellular uptake of polynucleotides by reducing or neutralizing the charge associated with anionically charged polynucleotides, and adding further functionality to the molecule, e.g., by including one or more auxiliary moieties.

[0169] The invention provides compositions and methods for the delivery of sequence specific polynucleotides useful for selectively treating human disorders and for promoting research. The compositions and methods of the invention effectively deliver polynucleotides (e.g., siRNAs) to subjects and to cells. The invention provides compositions and methods which overcome size and charge limitations that make RNAi constructs difficult to deliver into cells or make the constructs undeliverable.

[0170] By neutralizing the anionic charge of nucleic acids (e.g., dsRNA), a nucleotide construct comprising a bioreversible group according to the invention can deliver nucleic acids into a cell in vitro and in vivo.

[0171] The invention provides compositions and methods for the delivery of nucleotide constructs containing one or more targeting moieties for targeted delivery to specific cells (e.g., cells having asialoglycoprotein receptors on their surface (e.g., hepatocytes), tumor cells (e.g., tumor cells having folate receptors on their surface), cells bearing mannose receptor (e.g., macrophages, dendritic cells, and skin cells (e.g., fibroblasts or keratinocytes))). Non-limiting examples of mannose receptor superfamily include MR, Endo180, PLA2R, MGL, and DEC205. Targeted delivery of the nucleotide constructs of the invention may involve receptor mediated internalization. In some embodiments, targeting moieties may include mannose, N-acetyl galactosamine (GalNAc), or a folate ligand. In other embodiments, a targeting moiety may include one or more (e, g., from 1 to 5 or from 1 to 3) antibodies or antigen-binding fragments thereof. Certain targeting moieties include one antibody or antigen-binding fragment thereof.

[0172] The invention provides hybridized polynucleotide constructs having one or more non-bioreversible, and optionally bioreversible, moieties that contribute to chemical and biophysical properties that enhance cellular membrane penetration and resistance to exo- and endonuclease degradation. The invention further provides reagents for the synthesis of the hybridized polynucleotide constructs disclosed herein, e.g., phosphoramidate reagents.

[0173] In cells, the bioreversible moieties can be removed by the action of enzymes (e.g., enzymes having thioreductase activity (e.g., protein disulfide isomerase or thioredoxin)) or by exposure to the intracellular conditions (e.g., an oxidizing or reducing environment) or reactants (e.g., glutathione or other free thiol) to yield biologically active polynucleotide compounds that are capable of hybridizing to and/or having an affinity for specific endogenous nucleic acids.

[0174] Auxiliary Moieties Non-Bioreversibly Linked to Polynucleotide Constructs

[0175] The hybridized polynucleotide constructs of the invention may include an auxiliary moiety (e.g., a targeting moiety) non-bioreversibly linked to a phosphate or a phosphorothioate in the passenger strand of the hybridized polynucleotide construct. The auxiliary moiety can be non-bioreversibly linked to the phosphate or the phosphorothioate by a process described in the sections below. In some instances, the auxiliary moiety may be non-bioreversibly linked to the phosphate or the phosphorothioate through a linker containing 1,2,3-triazole or N-sulfonylamidocarbonyl. For example, the auxiliary moiety may combine with the non-bioreversible linker to form a group that is

##STR00010##

[0176] where

[0177] R is said auxiliary moiety (e.g., a targeting moiety);

[0178] R.sup.B is H or C.sub.1-6 alkyl; and L is C.sub.2-6 alkylene or (CH.sub.2CH.sub.2O).sub.p1(CH.sub.2CH.sub.2), where p1 is an integer from 1 to 50 (e.g., from 1 to 3, from 1 to 8, from 1 to 10, from 1 to 20, from 1 to 30, or from 1 to 40).

[0179] In some embodiments, the auxiliary moieties in the hybridized polynucleotide construct are linked to the passenger strand. At least some of the auxiliary moieties may be linked to internucleoside phosphates or phosphorothioates in the following pattern: N-p.sup.L-(N-p-)z-N-p.sup.L-(N-p-)z-N-p.sup.L-[(N-p-)z-N-p.sup.L].sub.z1-, where each N is independently a nucleoside; each p.sup.L is a phosphate or phosphorothioate non-bioreversibly linked to an auxiliary moiety; each p is independently a phosphate, phosphorothioate, phosphoramidate, or phosphonate; each z is independently 0, 1, or 2; and z1 is 0, 1, or 2.

[0180] Auxiliary Moieties Bioreversibly Linked to Polynucleotide Constructs

[0181] The hybridized polynucleotide constructs of the invention may include an auxiliary moiety bioreversibly linked to the passenger strand or the guide strand (e.g., a targeting moiety bioreversibly linked to a phosphate or phosphorothioate). The bioreversible linker connecting the auxiliary moiety to the passenger strand or the guide strand may include SS. For example, the bioreversible linker may combine with the auxiliary moiety to form R-(Link C)SS-(Link A)-, where R is the auxiliary moiety; Link A is a divalent or a trivalent linker containing an sp.sup.3-hybridized carbon atom bonded to the phosphate or phosphorothioate and a carbon atom bonded to SS, where the shortest chain of atoms between SS and the phosphate or the phosphorothioate is at least 3 atoms long (e.g., the shortest chain of atoms between SS and the phosphate or the phosphorothioate is from 3 to 6 (e.g., 4) atoms long); and Link C is a bond or a divalent or a trivalent linker having a molecular weight of from 13 Da to 1 kDa; [0182] where, when Link A is a trivalent linker, Link C is a trivalent linker and the third valency of Link A combines with SS and Link C to form optionally substituted C.sub.3-9 heterocyclylene or optionally substituted (C.sub.3-9 heterocyclyl)-C.sub.1-4-alkylene.

[0183] In some embodiments, the auxiliary moieties in the hybridized polynucleotide construct are linked to the passenger strand. At least some of the auxiliary moieties may be linked to internucleoside phosphates or phosphorothioates in the following pattern: N-p.sup.L-(N-p-).sub.z-N-p.sup.L-(N-p-).sub.z-N-p.sup.L-[(N-p-).sub.z-N-p.sup.L].sub.z1-, where each N is independently a nucleoside; each p.sup.L is a phosphate or phosphorothioate bioreversibly linked to an auxiliary moiety; each p is independently a phosphate, phosphorothioate, phosphoramidate, or phosphonate; each z is independently 0, 1, or 2; and z1 is 0, 1, or 2.

[0184] Link A can be optionally substituted C.sub.3-6 alkylene, optionally substituted (C.sub.6-14 aryl)-C.sub.1-4 alkylene, optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4 alkylene, or optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4 alkylene. For example, Link A can be

##STR00011##

where

[0185] R.sup.G is a halogen or optionally substituted C.sub.1-6 alkyl, and

[0186] q is an integer from 0 to 4 (e.g., q is 0).

[0187] Link C can include 1,2,3-triazole bonding to R. For example, Link C can combine with R, SS, and Link A to form:

##STR00012##

[0188] where R.sup.B is H or C.sub.1-6 alkyl.

[0189] Including sterically-hindered disulfides in the bioreversible linkers is particularly advantageous. Disulfides bonded to at least one bulky group exhibit greater stability during the polynucleotide construct synthesis compared to disulfides that are not bonded to at least one bulky group, as the latter may react with a phosphorus (III) atom of the nucleotide construct to cleave the disulfide bond.

[0190] Non-Bioreversible Phosphotriesters

[0191] The hybridized polynucleotide constructs of the invention may also include a non-bioreversible phosphotriester (e.g., a phosphate or a phosphorothioate that is substituted with a group that does not include a disulfide or a thioester). The non-bioreversible phosphotriester can be an internucleoside non-bioreversible phosphotriester (e.g., a non-bioreversible phosphotriester disposed outside the seed region of the hybridized polynucleotide construct). Preferred positions for internucleoside non-bioreversible phosphotriesters in the guide strand are those between the second and third nucleosides, the fifth and the sixth nucleosides, the seventeenth and the eighteenth nucleosides, the nineteeneth and the twentieth nucleosides, or the twentieth and the twenty first nucleosides (the count starts at 5-terminus of the guide strand). Preferred positions for the non-bioreversible phosphotriesters in the passenger strand are those that do not connect two contiguous nucleosides at the natural RISC-mediated cleavage site.

[0192] The non-bioreversible phosphotriester may be a phosphate or a phosphorothioate substituted with a substituent selected independently from the group consisting of optionally substituted C.sub.2-16 alkyl; optionally substituted C.sub.3-16 alkenyl; optionally substituted C.sub.3-16 alkynyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted C.sub.3-8 cycloalkenyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted (C.sub.3-8 cycloalkenyl)-C.sub.1-4-alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from N, O, and S, where the heterocyclyl does not contain an SS bond; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S, where the heterocyclyl does not contain an SS bond; and a group of the following structure:

##STR00013##

[0193] where [0194] L is optionally substituted C.sub.2-16 alkylene; [0195] R.sup.A is optionally substituted C.sub.2-6 alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from the group consisting of N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from the group consisting of N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from the group consisting of N, O, and S, wherein said heterocyclyl does not comprise an SS bond; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S, wherein said heterocyclyl does not comprise an SS bond; and a poly(ethylene glycol) terminated with OH, C.sub.1-6 alkoxy, or COOH; and [0196] R.sup.B is H or optionally substituted C.sub.1-6 alkyl.

[0197] The non-bioreversible phosphotriester may be a phosphate or a phosphorothioate substituted with a substituent that is

##STR00014##

or a group formed by cycloaddition reaction of

##STR00015##

with an azido-containing substrate,

[0198] where

[0199] n is an integer from 1 to 6;

[0200] n1 is an integer from 1 to 6 (e.g., from 1 to 4);

[0201] R.sup.C is optionally substituted C.sub.6 aryl; optionally substituted C.sub.4-5 heteroaryl that is a six member ring comprising 1 or 2 nitrogen atoms; or optionally substituted C.sub.4-5 heterocyclyl that is a six member ring comprising 1 or 2 nitrogen atoms;

[0202] R.sup.D is H or C.sub.1-6 alkyl;

[0203] each R.sup.D1 is independently H or C.sub.1-6 alkyl, provided that

##STR00016##

n contains 24 carbon atoms or fewer;

[0204] X is a halogen, COOR.sup.1, or CONR.sup.2.sub.2, where each of R.sup.1 and R.sup.2 is independently H, optionally substituted C.sub.1-6 alkyl, optionally substituted C.sub.6-14 aryl, optionally substituted C.sub.1-9 heteroaryl, or optionally substituted C.sub.2-9 heterocyclyl; and

[0205] the azido-containing substrate is

##STR00017##

[0206] Bioreversible Phosphotriesters

[0207] The hybridized polynucleotide constructs of the invention may also include a bioreversible phosphotriester (e.g., a phosphate or a phosphorothioate that is substituted with a group that includes a disulfide linked to the phosphate or the phosphorothioate through a linker includes sp.sup.3-carbon bonded to the phosphate and that includes the shortest chain of atoms of 3 to 6 atoms between disulfide and the phosphate or the phosphorothioate).

[0208] The bioreversible phosphotriester may be a phosphate or a phosphorothioate substituted with -(Link A)-SSR.sup.E, in which

[0209] Link A is a divalent or a trivalent linker containing an sp.sup.3-hybridized carbon atom bonded to the phosphate or phosphorothioate and a carbon atom bonded to SS, where, when Link A is a trivalent linker, the third valency of Link A combines with SS and R.sup.E to form optionally substituted 03-9 heterocyclylene, and

[0210] R.sup.E is optionally substituted C.sub.2-8 alkyl; optionally substituted C.sub.3-8 alkenyl; optionally substituted C.sub.3-8 alkynyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted C.sub.3-8 cycloalkenyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted (C.sub.3-8 cycloalkenyl)-C.sub.1-4-alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; or, when Link A is a trivalent linker, R.sup.E combines with SS and Link A to form optionally substituted C.sub.3-9 heterocyclyl.

[0211] The bioreversible phosphotriester may be a phosphate or a phosphorothioate substituted with a group that is

##STR00018##

[0212] where

[0213] R.sup.F is optionally substituted C.sub.1-6 alkyl or optionally substituted C.sub.6-14 aryl (e.g., R.sup.F is optionally substituted C.sub.1-6 alkyl),

[0214] R.sup.G is a halogen or optionally substituted C.sub.1-6 alkyl, and

[0215] q is an integer from 0 to 4 (e.g., q is 0).

[0216] In any of the bioreversible linkers described herein, SS may be replaced with C(O)S.

[0217] Including sterically-hindered disulfides in the bioreversible phosphotriesters is particularly advantageous. Disulfides bonded to at least one bulky group exhibit greater stability during the nucleotide construct synthesis compared to disulfides that are not bonded to at least one bulky group, as the latter may react with a phosphorus (III) atom of the nucleotide construct to cleave the disulfide bond.

[0218] Auxiliary Moieties

[0219] Various auxiliary moieties can be conjugated to the polynucleotide constructs of the invention, and the auxiliary moieties can provide desirable biological or chemical effects. Biological effects include, but are not limited to, inducing intracellularization, binding to a cell surface, targeting a specific cells type, allowing endosomal escape, altering the half-life of the polynucleotide in vivo, and providing a therapeutic effect. Chemical effects include, but are not limited to, changing the solubility, charge, size, and reactivity.

[0220] Targeting Moieties

[0221] The hybridized polynucleotide constructs disclosed herein may include one or more targeting moieties as auxiliary moieties. A targeting moiety is selected based on its ability to target constructs of the invention to a desired or selected cell population that expresses the corresponding binding partner (e.g., either the corresponding receptor or ligand) for the selected targeting moiety. For example, a construct of the invention could be targeted to hepatocytes expressing asialoglycoprotein (ASGP-R) by selecting a targeting moiety containing N-acetyl galactosamine (GalNAc) as the ligand. A targeting moiety (i.e., an intracellular targeting moiety) that targets a desired site within the cell (e.g., endoplasmic reticulum, Golgi apparatus, nucleus, or mitochondria) may be included in the hybridized polynucleotide constructs disclosed herein. Non-limiting examples of the intracellular targeting moieties are provided in WO 2015/069932 and in WO 2015/188197; the disclosure of the intracellular targeting moieties in WO 2015/069932 and in WO 2015/188197 is incorporated herein by reference.

[0222] A polynucleotide construct of the invention, thus, may include one or more targeting moieties selected from the group consisting of intracellular targeting moieties, extracellular targeting moieties, and combinations thereof. Thus, the inclusion of one or more targeting moieties (e.g., extracellular targeting moieties including ligands independently selected from the group consisting of folate, mannose, N-acetyl galactosamine, or prostate specific membrane antigen) and one or more intracellular targeting moiety (e.g., a moiety targeting endoplasmic reticulum, Golgi apparatus, nucleus, or mitochondria) in the polynucleotide construct of the invention can facilitate the delivery of the polynucleotides to a specific site within the specific cell population. In some embodiments, the targeting moiety contains one or more mannose carbohydrates. Mannose targets the mannose receptor, which is a 175 KDa membrane-associated receptor that is expressed on sinusoidal liver cells and antigen presenting cells (e.g., macrophages and dendritic cells). It is a highly effective endocytotic/recycling receptor that binds and internalizes mannosylated pathogens and proteins (Lennartz et. al. J. Biol. Chem. 262:9942-9944, 1987; Taylor et. al. J. Biol. Chem. 265:12156-62, 1990).

[0223] Some of the targeting moieties of the invention are described herein. In some embodiments, the targeting moiety contains or specifically binds to a protein selected from the group including insulin, insulin-like growth factor receptor 1 (IGF1R), IGF2R, insulin-like growth factor (IGF; e.g., IGF 1 or 2), mesenchymal epithelial transition factor receptor (c-met; also known as hepatocyte growth factor receptor (HGFR)), hepatocyte growth factor (HGF), epidermal growth factor receptor (EGFR), epidermal growth factor (EGF), heregulin, fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), platelet-derived growth factor (PDGF), vascular endothelial growth factor receptor (VEGFR), vascular endothelial growth factor (VEGF), tumor necrosis factor receptor (TNFR), tumor necrosis factor alpha (TNF-), TNF-, folate receptor (FOLR), folate, transferrin, transferrin receptor (TfR), mesothelin, Fc receptor, c-kit receptor, c-kit, an integrin (e.g., an 4 integrin or a -1 integrin), P-selectin, sphingosine-1-phosphate receptor-1 (S1PR), hyaluronate receptor, leukocyte function antigen-1 (LFA-1), CD4, CD11, CD18, CD20, CD25, CD27, CD52, CD70, CD80, CD85, CD95 (Fas receptor), CD106 (vascular cell adhesion molecule 1 (VCAM1), CD166 (activated leukocyte cell adhesion molecule (ALCAM)), CD178 (Fas ligand), CD253 (TNF-related apoptosis-inducing ligand (TRAIL)), ICOS ligand, CCR2, CXCR3, CCR5, CXCL12 (stromal cell-derived factor 1 (SDF-1)), interleukin 1 (IL-1), IL-1ra, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, CTLA-4, MART-1, gp100, MAGE-1, ephrin (Eph) receptor, mucosal addressin cell adhesion molecule 1 (MAdCAM-1), carcinoembryonic antigen (CEA), Lewis.sup.Y, MUC-1, epithelial cell adhesion molecule (EpCAM), cancer antigen 125 (CA125), prostate specific membrane antigen (PSMA), TAG-72 antigen, and fragments thereof. In further embodiments, the targeting moiety contains erythroblastic leukemia viral oncogene homolog (ErbB) receptor (e.g., ErbB1 receptor; ErbB2 receptor; ErbB3 receptor; and ErbB4 receptor). In some embodiments, the targeting moiety contains one or more (e.g., from 1 to 6) N-acetyl galactosamines (GalNAc). In certain embodiments, the targeting moiety contains one or more (e.g., from 1 to 6) mannoses. In other embodiments, the targeting moiety contains a folate ligand. The folate ligand has the structure:

##STR00019##

[0224] Certain targeting moieties may include bombesin, gastrin, gastrin-releasing peptide, tumor growth factors (TGF) (e.g., TGF- or TGF-), or vaccinia virus growth factor (VVGF). Non-peptidyl ligands can also be used in the targeting moieties and may include, for example, steroids, carbohydrates, vitamins, and lectins. Some targeting moieties may include a polypeptide, such as somatostatin or somatostatin analog (e.g., octreotide or lanreotide), bombesin, or an antibody or antigen-binding fragment thereof. Antibodies may be of any recognized class or subclass, e.g., IgG, IgA, IgM, IgD, or IgE. Typical are those antibodies which fall within the IgG class. The antibodies can be derived from any species according techniques known in the art. Typically, however, the antibody is of human, murine, or rabbit origin. In addition, the antibody may be polyclonal or monoclonal, but is typically monoclonal. Human or chimeric (e.g., humanized) antibodies may be used in targeting moieties. Targeting moieties may include an antigen-binding fragment of an antibody. Such antibody fragments may include, for example, the Fab, F(ab)2, Fv, or Fab fragments, singledomain antibody, ScFv, or other antigen-binding fragments. Fc fragments may also be employed in targeting moieties. Such antibody fragments can be prepared, for example, by proteolytic enzyme digestion, for example, by pepsin or papain digestion, reductive alkylation, or recombinant techniques. The materials and methods for preparing antibody fragments are well-known to those skilled in the art. See, e.g., Parham, J. Immunology, 131:2895, 1983; Lamoyi et al., J. Immunological Methods, 56:235, 1983.

[0225] Other peptides for use as a targeting auxiliary moiety in nucleotide constructs of the invention can be selected from KiSS peptides and analogs, urotensin II peptides and analogs, GnRH I and II peptides and analogs, depreotide, vapreotide, vasoactive intestinal peptide (VIP), cholecystokinin (CCK), RGD-containing peptides, melanocyte-stimulating hormone (MSH) peptide, neurotensin, calcitonin, glutathione, YIGSR (leukocyte-avid peptides, e.g., P483H, which contains the heparin-binding region of platelet factor-4 (PF-4) and a lysine-rich sequence), atrial natriuretic peptide (ANP), -amyloid peptides, delta-opioid antagonists (such as ITIPP(psi)), annexin-V, endothelin, leukotriene B4 (LTB4), chemotactic peptides (e.g., N-formyl-methionyl-leucyl-phenylalanine-lysine (fMLFK), GP Ilb/Illa receptor antagonists (e.g., DMP444), human neutrophil elastase inhibitor (EPI-HNE-2 and EPI-HNE-4), plasmin inhibitor, antimicrobial peptides, apticide (P280 and P274), thrombospondin receptor (including analogs such as TP-1300), bitistatin, pituitary adenylyl cyclase type I receptor (PAC1), fibrin -chain, peptides derived from phage display libraries, and conservative substitutions thereof.

[0226] The targeting moiety can include a non-bioreversible linker linking ligand(s) in the targeting moiety to the conjugating moiety or to the reaction product thereof (e.g., 1,2,3-triazole). The non-bioreversible linker can include one or more monomers, where each monomer is independently optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.2-6 alkenylene; optionally substituted C.sub.2-6 alkynylene; optionally substituted C.sub.3-8 cycloalkylene; optionally substituted C.sub.3-8 cycloalkenylene; optionally substituted C.sub.6-14 arylene; optionally substituted C.sub.1-9 heteroarylene having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.1-9 heterocyclylene having 1 to 4 heteroatoms selected from N, O, and S; imino; optionally substituted N; O; or S(O).sub.m, wherein m is 0, 1, or 2. In some embodiments, each monomer is independently optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.3-8 cycloalkylene; optionally substituted C.sub.3-8 cycloalkenylene; optionally substituted C.sub.6-14 arylene; optionally substituted C.sub.1-9 heteroarylene having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.1-9 heterocyclylene having 1 to 4 heteroatoms selected from N, O, and S; imino; optionally substituted N; O; or S(O).sub.m, where m is 0, 1, or 2 (e.g., m is 2). In certain embodiments, each monomer is independently optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.3-8 cycloalkylene; optionally substituted C.sub.3-8 cycloalkenylene; optionally substituted C.sub.6-14 arylene; optionally substituted C.sub.1-9 heteroarylene having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.1-9 heterocyclylene having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted N; O; or S(O).sub.m, where m is 0, 1, or 2 (e.g., m is 2). The non-bioreversible linker connecting the ligand to the conjugating moiety or to the reaction product thereof can include from 2 to 500 (e.g., from 2 to 300 or from 2 to 200) of such monomers. The non-bioreversible linker may include a poly(alkylene oxide) (e.g., polyethylene oxide, polypropylene oxide, poly(trimethylene oxide), polybutylene oxide, poly(tetramethylene oxide), and diblock or triblock copolymers thereof). In some embodiments, the non-bioreversible linker includes polyethylene oxide (e.g., poly(ethylene oxide) having a molecular weight of less than 1 kDa).

[0227] In some embodiments, the targeting moiety includes one or more (e.g., from 1 to 6 or from 1 to 3) GalNAc ligands. GalNAc ligand may be attached to a linker (e.g., as a ketal or a hemiaminal) which is further attached to a conjugating moiety or a reaction product thereof (e.g., 1,2,3-triazole). The linker can be as described herein. GalNAc ligands attached to a linker through a hemiaminal may produce hybridized polynucleotide constructs having superior efficacy in gene silencing as compared to hybridized polynucleotide constructs having GalNAc ligand(s) attached to a linker through a ketal.

[0228] Endosomal Escape Moieties

[0229] The invention provides for one or more endosomal escape moieties which can be attached to a nucleotide construct disclosed herein as an auxiliary moiety, for example, as an endosomal escape auxiliary moiety. Exemplary endosomal escape moieties include chemotherapeutics (e.g., quinolones such as chloroquine); fusogenic lipids (e.g., dioleoylphosphatidyl-ethanolamine (DOPE)); and polymers such as polyethylenimine (PEI); poly(beta-amino ester)s; peptides or polypeptides such as polyarginines (e.g., octaarginine) and polylysines (e.g., octalysine); proton sponges, viral capsids, and peptide transduction domains as described herein. For example, fusogenic peptides can be derived from the M2 protein of influenza A viruses; peptide analogs of the influenza virus hemagglutinin; the HEF protein of the influenza C virus; the transmembrane glycoprotein of filoviruses; the transmembrane glycoprotein of the rabies virus; the transmembrane glycoprotein (G) of the vesicular stomatitis virus; the fusion protein of the Sendai virus; the transmembrane glycoprotein of the Semliki forest virus; the fusion protein of the human respiratory syncytial virus (RSV); the fusion protein of the measles virus; the fusion protein of the Newcastle disease virus; the fusion protein of the visna virus; the fusion protein of murine leukemia virus; the fusion protein of the HTL virus; and the fusion protein of the simian immunodeficiency virus (SIV). Other moieties that can be employed to facilitate endosomal escape are described in Dominska et al., Journal of Cell Science, 123(8):1183-1189, 2010. Specific examples of endosomal escape moieties including moieties suitable for conjugation to the hybridized polynucleotide constructs disclosed herein are provided, e.g., in PCT/US2015/034749; the disclosure of these endosomal escape moieties is incorporated by reference herein.

[0230] An endosomal escape moiety can include a non-bioreversible linker attaching the endosomal escape moiety to the conjugating moiety or a reaction product thereof (e.g., 1,2,3-triazole). The linker can be as described above for targeting moieties.

[0231] Cell Penetrating Peptides

[0232] The hybridized polynucleotide constructs disclosed herein may include a cell penetrating peptide (CPP) bioreversibly or non-bioreversibly linked to the hybridized polynucleotide construct. The CPP can be linked to the hybridized polynucleotide bioreversibly through a disulfide linkage, as disclosed herein. Thus, upon delivery to a cell, the CPP can be cleaved intracellularly, e.g., by an intracellular enzyme (e.g., protein disulfide isomerase, thioredoxin, or a thioesterase) and thereby release the polynucleotide.

[0233] CPPs are known in the art (e.g., TAT or Arg8) (Snyder and Dowdy, 2005, Expert Opin. Drug Deliv. 2, 43-51). Specific examples of CPPs including moieties suitable for conjugation to the hybridized polynucleotide constructs disclosed herein are provided, e.g., in PCT/US2015/034749; the disclosure of these CPPs is incorporated by reference herein.

[0234] CPPs are positively charged peptides that are capable of facilitating the delivery of biological cargo to a cell. It is believed that the cationic charge of the CPPs is essential for their function. Moreover, the transduction of these proteins does not appear to be affected by cell type, and these proteins can efficiently transduce nearly all cells in culture with no apparent toxicity (Nagahara et al., Nat. Med. 4:1449-52, 1998). In addition to full-length proteins, CPPs have also been used successfully to induce the intracellular uptake of DNA (Abu-Amer, supra), antisense polynucleotides (Astriab-Fisher et al., Pharm. Res, 19:744-54, 2002), small molecules (Polyakov et al., Bioconjug. Chem. 11:762-71, 2000) and even inorganic 40 nm iron particles (Dodd et al., J. Immunol. Methods 256:89-105, 2001; Wunderbaldinger et al., Bioconjug. Chem. 13:264-8, 2002; Lewin et al., Nat. Biotechnol. 18:410-4, 2000; Josephson et al., Bioconjug. Chem. 10:186-91, 1999) suggesting that there is considerable flexibility in particle size in this process.

[0235] In one embodiment, a CPP useful in the methods and compositions of the invention includes a peptide featuring substantial alpha-helicity. It has been discovered that transfection is optimized when the CPP exhibits significant alpha-helicity. In another embodiment, the CPP includes a sequence containing basic amino acid residues that are substantially aligned along at least one face of the peptide. A CPP useful in the invention may be a naturally occurring peptide or a synthetic peptide.

[0236] CPPs can be linked through a non-bioreversible linker to the conjugating moiety or a reaction product thereof (e.g., 1,2,3-triazole).

[0237] Polymers

[0238] The nucleotide constructs described herein can also include covalently attached neutral polymer-based auxiliary moieties. Neutral polymers include poly(C.sub.1-6 alkylene oxide), e.g., poly(ethylene glycol) and poly(propylene glycol) and copolymers thereof, e.g., di- and triblock copolymers. Other examples of polymers include esterified poly(acrylic acid), esterified poly(glutamic acid), esterified poly(aspartic acid), poly(vinyl alcohol), poly(ethylene-co-vinyl alcohol), poly(N-vinyl pyrrolidone), poly(ethyloxazoline), poly(alkylacrylates), poly(acrylamide), poly(N-alkylacrylamides), poly(N-acryloylmorpholine), poly(lactic acid), poly(glycolic acid), poly(dioxanone), poly(caprolactone), styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolide) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyurethane, N-isopropylacrylamide polymers, and poly(N,N-dialkylacrylamides). Exemplary polymer auxiliary moieties may have molecular weights of less than 100, 300, 500, 1000, or 5000 Da (e.g., greater than 100 Da). Other polymers are known in the art.

[0239] The polymers can be attached to a conjugating moiety or a reaction product thereof (e.g., 1,2,3-triazole).

[0240] Preparation of the Polynucleotide Constructs

[0241] The invention further provides methods for manufacturing the polynucleotide constructs of the invention. Methods for the preparation of nucleotides and polynucleotides are known in the art. For example, the practice of phosphoramidite chemistry to prepare polynucleotides is known from the published work of Caruthers and Beaucage and others. See, e.g., U.S. Pat. Nos. 4,458,066; 4,500,707; 5,132,418; 4,415,732; 4,668,777; 4,973,679; 5,278,302, 5,153,319; 5,218,103; 5,268,464; 5,000,307; 5,319,079; 4,659,774; 4,672,110; 4,517,338; 4,725,677; and RE34,069, each of which is herein incorporated by reference, describe methods of polynucleotide synthesis. Additionally, the practice of phosphoramidite chemistry has been systematically reviewed by Beaucage et al., Tetrahedron, 48: 2223-2311, 1992; and Beaucage et al., Tetrahedron, 49:6123-6194, 1993, as well as references referred to therein, all of which are herein incorporated by reference. Synthesis principles useful in the synthesis of the polynucleotide constructs of the invention are disclosed in PCT/US2014/064401 and in PCT/US2015/034749; the disclosure of syntheses of polynucleotide constructs in PCT/US2014/064401 and in PCT/US2015/034749 is incorporated herein by reference.

[0242] Nucleic acid synthesizers are commercially available, and their use is generally understood by persons of ordinary skill in the art as being effective in generating nearly any polynucleotide of reasonable length which may be desired.

[0243] In practicing phosphoramidite chemistry, useful 5OH sugar blocking groups are trityl, monomethoxytrityl, dimethoxytrityl and trimethoxytrityl, especially dimethoxytrityl (DMTr). In practicing phosphoramidite chemistry, useful phosphite activating groups are dialkyl substituted nitrogen groups and nitrogen heterocycles. One approach includes the use of the di-isopropylamino activating group.

[0244] Polynucleotides can be synthesized by a Mermade-6 solid phase automated polynucleotide synthesizer or any commonly available automated polynucleotide synthesizer. Triester, phosphoramidite, or hydrogen phosphonate coupling chemistries (described in, for example, M. Caruthers, Oligonucleotides: Antisense Inhibitors of Gene Expression, pp. 7-24, J. S. Cohen, ed. (CRC Press, Inc. Boca Raton, Fla., 1989); Oligonucleotide synthesis, a practical approach, Ed. M. J. Gait, IRL Press, 1984; and Oligonucleotides and Analogues, A Practical Approach, Ed. F. Eckstein, IRL Press, 1991) are employed by these synthesizers to provide the desired polynucleotides. The Beaucage reagent, as described in, for example, Journal of American Chemical Society, 112:1253-1255, 1990, or elemental sulfur, as described in Beaucage et al., Tetrahedron Letters 22:1859-1862, 1981, is used with phosphoramidite or hydrogen phosphonate chemistries to provide substituted phosphorothioate polynucleotides.

[0245] For example, the reagents containing the protecting groups recited herein can be used in numerous applications where protection is desired. Such applications include, but are not limited to, both solid phase and solution phase, polynucleotide synthesis and the like.

[0246] For instance, structural groups are optionally added to the ribose or base of a nucleoside for incorporation into a polynucleotide, such as a methyl, propyl or allyl group at the 2-0 position on the ribose, or a fluoro group which substitutes for the 2-O group, or a bromo group on the ribonucleoside base. For use with phosphoramidite chemistry, various phosphoramidite reagents are commercially available, including 2-deoxy phosphoramidites, 2-O-methyl phosphoramidites and 2-O-hydroxyl phosphoramidites. Any other means for such synthesis may also be employed. The actual synthesis of the polynucleotides is well within the talents of those skilled in the art. It is also well known to use similar techniques to prepare other polynucleotides such as the phosphorothioates, methyl phosphonates and alkylated derivatives. It is also well known to use similar techniques and commercially available modified phosphoramidites and controlled-pore glass (CPG) products such as biotin, Cy3, fluorescein, acridine or psoralen-modified phosphoramidites and/or CPG (available from Glen Research, Sterling Va.) to synthesize fluorescently labeled, biotinylated or other conjugated polynucleotides.

[0247] The phosphoramidite reagents useful for the preparation of the polynucleotide constructs of the invention can be of the following structure:

##STR00020##

or a salt thereof,

[0248] B.sup.1 is a nucleobase;

[0249] X is O, S, or optionally substituted N;

[0250] Y is a H, hydroxyl, halogen, optionally substituted C.sub.1-6 alkoxy, or a protected hydroxyl group;

[0251] Y.sup.1 is independently H or optionally substituted C.sub.1-6 alkyl (e.g., methyl);

[0252] R.sup.1 is protected hydroxyl (e.g., hydroxyl protected with 4,4-dimethoxytrityl group (DMT));

[0253] R.sup.2 is N(R.sup.4)R.sup.6 or N(C.sub.1-6 alkyl).sub.2 (e.g., N(iPr).sub.2); and

[0254] R.sup.3 is optionally substituted C.sub.2-16 alkyl; optionally substituted C.sub.3-16 alkenyl; optionally substituted C.sub.3-16 alkynyl; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted C.sub.3-8 cycloalkenyl; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkyl; optionally substituted (C.sub.3-8 cycloalkenyl)-C.sub.1-4-alkyl; optionally substituted C.sub.6-14 aryl; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkyl; optionally substituted C.sub.1-9 heteroaryl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from N, O, and S, where the heterocyclyl does not comprise an SS bond; optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkyl having 1 to 4 heteroatoms selected from N, O, and S, where the heterocyclyl does not comprise an SS bond, or a group that is

##STR00021##

[0255] where A.sup.1 is a bond or a linker containing or consisting of one or more of optionally substituted N, O, S, optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.2-6 alkenylene; optionally substituted C.sub.2-6 alkynylene; optionally substituted C.sub.3-8 cycloalkylene; optionally substituted C.sub.3-8 cycloalkenylene; optionally substituted (C.sub.3-8 cycloalkyl)-C.sub.1-4-alkylene; optionally substituted (C.sub.3-8 cycloalkenyl)-C.sub.1-4-alkylene; optionally substituted C.sub.6-14 arylene; optionally substituted (C.sub.6-14 aryl)-C.sub.1-4-alkylene; optionally substituted C.sub.1-9 heteroarylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; optionally substituted (C.sub.1-9 heteroaryl)-C.sub.1-4-alkylene having 1 to 4 heteroatoms selected from nitrogen, oxygen; optionally substituted C.sub.2-9 heterocyclylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; and optionally substituted (C.sub.2-9 heterocyclyl)-C.sub.1-4-alkylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur, provided that when A.sup.1 comprises one or more of amino, O, and S, none of the amino, O, and S is directly bonded to the disulfide; and A.sup.2 is selected from the group consisting of optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.3-8 cycloalkylene; optionally substituted C.sub.3-8 cycloalkenylene; optionally substituted C.sub.6-14 arylene; optionally substituted C.sub.1-9 heteroarylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; and optionally substituted C.sub.2-9 heterocyclylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; or A.sup.1 and A.sup.2, together with SS, join to form an optionally substituted 5 to 16 membered ring;

[0256] A.sup.3 is selected from the group consisting of a bond, optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.3-8 cycloalkylene; optionally substituted C.sub.3-8 cycloalkenylene; optionally substituted C.sub.6-14 arylene, optionally substituted C.sub.1-9 heteroarylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; optionally substituted C.sub.2-9 heterocyclylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; 0; optionally substituted N; and S;

[0257] A.sup.4 is selected from the group consisting of optionally substituted C.sub.1-6 alkylene; optionally substituted C.sub.3-8 cycloalkylene; and optionally substituted C.sub.2-9 heterocyclylene having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur;

[0258] L is a bond or a conjugating group including or consisting of one or more conjugating moieties;

[0259] R.sup.5 is hydrogen, optionally substituted C.sub.1-6 alkyl, a hydrophilic functional group, or a group comprising an auxiliary moiety selected from the group consisting of a small molecule, a peptide, a carbohydrate, a neutral organic polymer, a positively charged polymer, a therapeutic agent, a targeting moiety, an endosomal escape moiety, and combination thereof;

[0260] r is an integer from 1 to 10;

[0261] where A.sup.2, A.sup.3, and A.sup.4 combine to form a group having at least three atoms (e.g., from three to six (e.g., four)) in the shortest chain connecting SS and X; and

[0262] each R.sup.4 and R.sup.6 is independently selected from the group consisting of hydrogen; optionally substituted C.sub.1-6 alkyl; optionally substituted C.sub.2-7 alkanoyl; hydroxyl; optionally substituted C.sub.1-6 alkoxy; optionally substituted C.sub.3-8 cycloalkyl; optionally substituted C.sub.3-8 cycloalkenyl; optionally substituted C.sub.6-14 aryl; optionally substituted C.sub.6-15 aryloyl; optionally substituted C.sub.2-9 heterocyclyl having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur; and optionally substituted C.sub.3-1.sub.0 (heterocycle)oyl having 1 to 4 heteroatoms selected from nitrogen, oxygen, and sulfur.

[0263] The invention further provides methods to process a polynucleotide construct synthesized by using a method of manufacture disclosed herein. For example, post synthesis of the polynucleotide construct, if a nucleobase contains one or more protecting groups, the protecting groups may be removed; and/or for any -L-A.sup.1-SS-A.sup.2-A.sup.3-A.sup.4-containing a hydrophilic functional group or conjugating moiety that is protected by a protecting group, then the protecting group may be removed.

[0264] Additionally, post synthesis of the polynucleotide construct, a group containing one or more auxiliary moieties can be linked to one or more conjugating moieties of one or more bioreversible groups.

[0265] Conjugation

[0266] Preparation of polynucleotide constructs of the invention may involve conjugating an auxiliary moiety to a non-bioreversible or bioreversible linker attached to a phosphate or a phosphorothioate in the polynucleotide construct. The auxiliary moiety and the linker include complementary conjugating moieties. The location of attachment in a polynucleotide construct is determined by the positioning of the phosphates or phosphorothioates bearing the linker. Thus, a polynucleotide construct containing one more conjugating moieties will react, under appropriate conditions, with one or more complementary conjugating moieties on auxiliary moieties. The auxiliary moiety may intrinsically possess the conjugating moiety, e.g., terminal or lysine amine groups and thiol groups in peptides, or it may be modified to include a small linking group to introduce the conjugating moiety. Introduction of such linking groups is well known in the art. It will be understood that an auxiliary moiety attached to a nucleotide construct of the invention includes any necessary linking group.

[0267] Diverse bond-forming methods can be used to conjugate the auxiliary moiety to the nucleotide constructs described herein. Exemplary reactions include: cycloaddition between an azide and an alkyne to form a triazole; the Diels-Alder reaction between a dienophile and a diene/hetero-diene; bond formation via other pericyclic reactions such as the ene reaction; amide or thioamide bond formation; sulfonamide bond formation; alcohol or phenol alkylation (e.g., with diazo compounds), condensation reactions to form oxime, hydrazone, or semicarbazide group, conjugate addition reactions by nucleophiles (e.g., amines and thiols), disulfide bond formation, and nucleophilic substitution at a carboxylic functionality (e.g., by an amine, thiol, or hydroxyl nucleophile). Other exemplary methods of bond formation are described herein and known in the art.

[0268] Nucleophile/Electrophile Reactions

[0269] Nucleophiles and electrophiles can engage in bond forming reactions selected from, without limitation, insertion by an electrophile into a CH bond, insertion by an electrophile into an OH bond, insertion by an electrophile into an NH bond, addition of the electrophile across an alkene, addition of the electrophile across an alkyne, addition to electrophilic carbonyl centers, substitution at electrophilic carbonyl centers, addition to ketenes, nucleophilic addition to isocyanates, nucleophilic addition to isothiocyanates, nucleophilic substitution at activated silicon centers, nucleophilic displacement of an alkyl halide, nucleophilic displacement at an alkyl pseudohalide, nucleophilic addition/elimination at an activated carbonyl, 1,4-conjugate addition of a nucleophile to an ,-unsaturated carbonyl, nucleophilic ring opening of an epoxide, nucleophilic aromatic substitution of an electron deficient aromatic compound, a nucleophilic addition to activated phosphorus centers, nucleophilic substitution at activated phosphorous centers, nucleophilic addition to activated sulfur centers, and nucleophilic substitution at activated sulfur centers.

[0270] A nucleophilic conjugating moiety may be selected from optionally substituted alkenes, optionally substituted alkynes, optionally substituted aryl, optionally substituted heterocyclyl, hydroxyl groups, amino groups, alkylamino groups, anilido groups, and thio groups.

[0271] An electrophilic conjugating moiety may be selected from azides, activated silicon centers, activated carbonyls, anhydrides, isocyanates, thioisocyanates, succinimidyl esters, sulfosuccinimidyl esters, maleimides, alkyl halides, alkyl pseudohalides, epoxides, episulfides, aziridines, electron-deficient aryls, activated phosphorus centers, and activated sulfur centers.

[0272] For example, conjugation can occur via a condensation reaction to form a linkage that is a hydrazone bond.

[0273] Conjugation via the formation of an amide bond can be mediated by activation of a carboxyl-based conjugating moiety and subsequent reaction with a primary amine-based conjugating moiety. Activating agents can be various carbodiimides like: EDC (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), EDAC (1-ethyl-3(3-dimethylaminopropyl)carbodiimide hydrochloride), DCC (dicyclohexyl carbodiimide), CMC (1-Cyclohexyl-3-(2-morpholinoethyl) carbodiimide), DIC (diisopropyl carbodiimide) or Woodward's reagent K (N-ethyl-3-phenylisoxazolium-3-sulfonate). Reaction of an activated NHS-Ester-based conjugating moiety with a primary amine-based conjugating moiety also results in formation of an amide bond.

[0274] Ether formation can also be used to conjugate auxiliary moieties to the nucleotide constructs of the invention. Conjugation via ether linkages can be mediated by reaction of an epoxide-based conjugating moiety with a hydroxy-based conjugating moiety.

[0275] Thiols can also be used as conjugating moieties. For example, conjugation via the formation of disulfide bonds can be accomplished by pyridyldisulfide mediated thiol-disulfide exchange. Introduction of sulfhydryl-based conjugating moieties is mediated for instance by Traut's Reagent (2-iminothiolane) SATA (N-succinimidyl S-acetylthioacetate, SATP (succinimidyl acetylthiopropionate), SPDP (N-succinimidyl 3-(2-pyridyldithio)propionate, SMPT (succinimidyloxycarbonyl--methyl--(2-pyridyldithio)toluene), N-acetylhomocysteinethiolactone, SAMSA (S-acetylmercaptosuccinic anhydride), AMBH (2-Acedamido-4-mercaptobuturic acid hydrazide), and cystamine (2,2-dithiobis(ethylamine).

[0276] Conjugation via the formation of thioether linkages can be performed by reacting a sulfhydryl based conjugating moieties with maleimide- or iodoacetyl-based conjugating moieties or by reacting with epoxide-based conjugating moieties. Maleimide-based conjugating moieties can be introduced by SMCC (succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate), sulfo-SMCC (sulfosuccinimidyl 4-(N-maleidomethyl)-cyclohexane-1-carboxylate), MBS (m-Maleimidobenzoyl-N-hydroxysuccinimide ester), sulfo-MBS (m-Maleimidobenzoyl-N-sulfohydroxy succinimide ester), SMPB (Succinimidyl-4-(p-maleidophenyl)butyrate), sulfo-SMPB (sulfosuccinimidyl 4-(p-maleimidophenyl)butyrate), GMBS (N--maleimidobuturyl-oxysuccinimide ester), sulfo GMBS (N--maleimidobuturyl-oxysulfosuccinimide ester).

[0277] Conjugation via the formation of a carbamate linkage can be performed by reaction of a hydroxy-based conjugating moiety with CDI (N,N-carbonyldiimidazole) or DSC (N,N-disuccinimidyl carbonate) or N-hydroxysuccinimidylchloroformate and subsequent reaction with an amine-based conjugating moiety.

[0278] Photolytic and Thermolytic Conjugation

[0279] Alternatively, the conjugating moiety can employ photolytic or thermolytic activation in order to form the desired covalent bond. Conjugating moieties that include azido functionality are one example. Thus, conjugation can also be achieved by the introduction of a photoreactive conjugating moiety. Photoreactive conjugating moieties are aryl azides, halogenated aryl azides, benzophenones certain diazo compounds and diazirine derivatives. They react with amino-based conjugating moieties or with conjugating moieties that have activated hydrogen bonds.

[0280] The azido-based conjugating moieties are UV labile and, upon photolysis, can lead to the formation of nitrene electrophiles that can react with nucleophilic conjugating moieties such as aryl-based conjugating moieties or alkenyl-based conjugating moieties. Alternatively, the heating of these azido compounds can also result in nitrene formation.

[0281] Cycloaddition Reactions

[0282] Cycloaddition reactions can be used to form the desired covalent bond. Representative cycloaddition reactions include, but are not limited to, the reaction of an alkene-based conjugating moiety with a 1,3-diene-based conjugating moiety (Diels-Alder reaction), the reaction of an alkene-based conjugating moiety with an ,-unsaturated carbonyl-based conjugating moiety (hetero Diels-Alder reaction), and the reaction of an alkyne-based conjugating moiety with an azido-based conjugating moiety (Hisgen cycloaddition). Selected, non-limiting examples of conjugating moieties that include reactants for cycloaddition reactions are: alkenes, alkynes, 1,3-dienes, ,-unsaturated carbonyls, and azides. For example, the Hisgen cycloaddition (click reaction) between azides and alkynes has been used for the functionalization of diverse biological entities.

Pharmaceutical Compositions

[0283] Delivery of a nucleotide construct of the invention can be achieved by contacting a cell with the construct using a variety of methods known to those of skill in the art. In particular embodiments, a nucleotide construct of the invention is formulated with various carriers, dispersion agents and the like, as are described more fully elsewhere herein.

[0284] A pharmaceutical composition according to the invention can be prepared to include a nucleotide construct disclosed herein, into a form suitable for administration to a subject using carriers, excipients, and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol, and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers.

[0285] Preservatives include antimicrobial, anti-oxidants, chelating agents, and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington: The Science and Practice of Pharmacy, 21.sup.st Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2005), and The United States Pharmacopeia: The National Formulary (USP 36 NF31), published in 2013. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's, The Pharmacological Basis for Therapeutics.

[0286] The pharmaceutical compositions according to the invention may be administered locally or systemically. The therapeutically effective amounts will vary according to factors, such as the degree of infection in a subject, the age, sex, and weight of the individual. Dosage regimes can be adjusted to provide the optimum therapeutic response. For example, several divided doses can be administered daily or the dose can be proportionally reduced as indicated by the exigencies of the therapeutic situation.

[0287] The pharmaceutical composition can be administered in a convenient manner, such as by injection (e.g., subcutaneous, intravenous, intraorbital, and the like), oral administration, ophthalmic application, inhalation, transdermal application, topical application, or rectal administration. Depending on the route of administration, the pharmaceutical composition can be coated with a material to protect the pharmaceutical composition from the action of enzymes, acids, and other natural conditions that may inactivate the pharmaceutical composition. The pharmaceutical composition can also be administered parenterally or intraperitoneally. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms.

[0288] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. The composition will typically be sterile and fluid to the extent that easy syringability exists. Typically the composition will be stable under the conditions of manufacture and storage and preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size, in the case of dispersion, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, isotonic agents, for example, sugars, polyalcohols, such as mannitol, sorbitol, or sodium chloride are used in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.

[0289] Sterile injectable solutions can be prepared by incorporating the pharmaceutical composition in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the pharmaceutical composition into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.

[0290] The pharmaceutical composition can be orally administered, for example, with an inert diluent or an assimilable edible carrier. The pharmaceutical composition and other ingredients can also be enclosed in a hard or soft-shell gelatin capsule, compressed into tablets, or incorporated directly into the subject's diet. For oral therapeutic administration, the pharmaceutical composition can be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 1% by weight of active compound. The percentage of the compositions and preparations can, of course, be varied and can conveniently be between about 5% to about 80% of the weight of the unit. The tablets, troches, pills, capsules, and the like can also contain the following: a binder, such as gum tragacanth, acacia, corn starch, or gelatin; excipients such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid, and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin, or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring. When the dosage unit form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier. Various other materials can be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills, or capsules can be coated with shellac, sugar, or both. A syrup or elixir can contain the agent, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye, and flavoring, such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed. In addition, the pharmaceutical composition can be incorporated into sustained-release preparations and formulations.

[0291] Thus, a pharmaceutically acceptable carrier is intended to include solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the pharmaceutical composition, use thereof in the therapeutic compositions and methods of treatment is contemplated. Supplementary active compounds can also be incorporated into the compositions.

[0292] It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein, refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of pharmaceutical composition is calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are related to the characteristics of the pharmaceutical composition and the particular therapeutic effect to be achieve. The principal pharmaceutical composition is compounded for convenient and effective administration in effective amounts with a suitable pharmaceutically acceptable carrier in an acceptable dosage unit. In the case of compositions containing supplementary active ingredients, the dosages are determined by reference to the usual dose and manner of administration of the ingredients.

[0293] For topical formulations, the base composition can be prepared with any solvent system, such as those Generally Regarded as Safe (GRAS) by the U.S. Food & Drug Administration (FDA). GRAS solvent systems include many short chain hydrocarbons, such as butane, propane, n-butane, or a mixture thereof, as the delivery vehicle, which are approved by the FDA for topical use. The topical compositions can be formulated using any dermatologically acceptable carrier. Exemplary carriers include a solid carrier, such as alumina, clay, microcrystalline cellulose, silica, or talc; and/or a liquid carrier, such as an alcohol, a glycol, or a water-alcohol/glycol blend. The compounds may also be administered in liposomal formulations that allow compounds to enter the skin. Such liposomal formulations are described in U.S. Pat. Nos. 5,169,637; 5,000,958; 5,049,388; 4,975,282; 5,194,266; 5,023,087; 5,688,525; 5,874,104; 5,409,704; 5,552,155; 5,356,633; 5,032,582; 4,994,213; and PCT Publication No. WO 96/40061. Examples of other appropriate vehicles are described in U.S. Pat. Nos. 4,877,805, 4,980,378, 5,082,866, 6,118,020 and EP Publication No. 0586106A1. Suitable vehicles of the invention may also include mineral oil, petrolatum, polydecene, stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, or vegetable oil.

[0294] Topical compositions can be provided in any useful form. For example, the compositions of the invention may be formulated as solutions, emulsions (including microemulsions), suspensions, creams, foams, lotions, gels, powders, balm, or other typical solid, semi-solid, or liquid compositions used for application to the skin or other tissues where the compositions may be used. Such compositions may contain other ingredients typically used in such products, such as colorants, fragrances, thickeners, antimicrobials, solvents, surfactants, detergents, gelling agents, antioxidants, fillers, dyestuffs, viscosity-controlling agents, preservatives, humectants, emollients (e.g., natural or synthetic oils, hydrocarbon oils, waxes, or silicones), hydration agents, chelating agents, demulcents, solubilizing excipients, adjuvants, dispersants, skin penetration enhancers, plasticizing agents, preservatives, stabilizers, demulsifiers, wetting agents, sunscreens, emulsifiers, moisturizers, astringents, deodorants, and optionally including anesthetics, anti-itch actives, botanical extracts, conditioning agents, darkening or lightening agents, glitter, humectants, mica, minerals, polyphenols, silicones or derivatives thereof, sunblocks, vitamins, and phytomedicinals.

[0295] In some formulations, the composition is formulated for ocular application. For example, a pharmaceutical formulation for ocular application can include a polynucleotide construct as described herein in an amount that is, e.g., up to 99% by weight mixed with a physiologically acceptable ophthalmic carrier medium such as water, buffer, saline, glycine, hyaluronic acid, mannitol, and the like. For ophthalmic delivery, a polynucleotide construct as described herein may be combined with ophthalmologically acceptable preservatives, co-solvents, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, or water to form an aqueous, sterile ophthalmic suspension or solution. Ophthalmic solution formulations may be prepared by dissolving the polynucleotide construct in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the inhibitor. Viscosity building agents, such as hydroxymethyl cellulose, hydroxyethyl cellulose, methylcellulose, polyvinylpyrrolidone, or the like may be added to the compositions of the invention to improve the retention of the compound.

[0296] Topical compositions can be delivered to the surface of the eye, e.g., one to four times per day, or on an extended delivery schedule such as daily, weekly, bi-weekly, monthly, or longer, according to the routine discretion of a skilled clinician. The pH of the formulation can range from about pH 4-9, or about pH 4.5 to pH 7.4.

[0297] For nucleotide constructs of the invention, suitable pharmaceutically acceptable salts include (i) salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.; (ii) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; (iii) salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and the like; and (iv) salts formed from elemental anions such as chlorine, bromine, and iodine.

[0298] While the nucleotide constructs described herein may not require the use of a carrier for delivery to the target cell, the use of carriers may be advantageous in some embodiments. Thus, for delivery to the target cell, the nucleotide construct of the invention can non-covalently bind a carrier to form a complex. The carrier can be used to alter biodistribution after delivery, to enhance uptake, to increase half-life or stability of the polynucleotide (e.g., improve nuclease resistance), and/or to increase targeting to a particular cell or tissue type.

[0299] Exemplary carriers include a condensing agent (e.g., an agent capable of attracting or binding a nucleic acid through ionic or electrostatic interactions); a fusogenic agent (e.g., an agent capable of fusing and/or being transported through a cell membrane); a protein to target a particular cell or tissue type (e.g., thyrotropin, melanotropin, lectin, glycoprotein, surfactant protein A, or any other protein); a lipid; a lipopolysaccharide; a lipid micelle or a liposome (e.g., formed from phospholipids, such as phosphotidylcholine, fatty acids, glycolipids, ceramides, glycerides, cholesterols, or any combination thereof); a nanoparticle (e.g., silica, lipid, carbohydrate, or other pharmaceutically-acceptable polymer nanoparticle); a polyplex formed from cationic polymers and an anionic agent (e.g., a CRO), where exemplary cationic polymers include polyamines (e.g., polylysine, polyarginine, polyamidoamine, and polyethylene imine); cholesterol; a dendrimer (e.g., a polyamidoamine (PAMAM) dendrimer); a serum protein (e.g., human serum albumin (HSA) or low-density lipoprotein (LDL)); a carbohydrate (e.g., dextran, pullulan, chitin, chitosan, inulin, cyclodextrin, or hyaluronic acid); a lipid; a synthetic polymer, (e.g., polylysine (PLL), polyethylenimine, poly-L-aspartic acid, poly-L-glutamic acid, styrene-maleic acid anhydride copolymer, poly(L-lactide-co-glycolic) copolymer, divinyl ether-maleic anhydride copolymer, N-(2-hydroxypropyl)methacrylamide copolymer (HMPA), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polyurethane, poly(2-ethylacrylic acid), N-isopropylacrylamide polymer, pseudopeptide-polyamine, peptidomimetic polyamine, or polyamine); a cationic moiety (e.g., cationic lipid, cationic porphyrin, quaternary salt of a polyamine, or alpha helical peptide); a multivalent sugar (e.g., multivalent lactose, multivalent galactose, N-acetyl-galactosamine, N-acetyl-glucosamine, multivalent mannose, or multivalent fucose); a vitamin (e.g., vitamin A, vitamin E, vitamin K, vitamin B, folic acid, vitamin B12, riboflavin, biotin, or pyridoxal); a cofactor; or a drug to disrupt cellular cytoskeleton to increase uptake (e.g., taxol, vincristine, vinblastine, cytochalasin, nocodazole, japlakinolide, latrunculin A, phalloidin, swinholide A, indanocine, or myoservin).

[0300] Other therapeutic agents as described herein may be included in a pharmaceutical composition of the invention in combination with a nucleotide construct of the invention.

Intracellular Activity of the Hybridized Polynucleotide Constructs

[0301] The invention provides compositions and methods for delivering hybridized polynucleotide constructs disclosed herein. The invention therefore provides methods and compositions useful for delivery of non-coding nucleotide constructs that exert a regulating effect on gene or protein expression through RNA interference (RNAi). RNA interference (RNAi) is the process whereby messenger RNA (mRNA) is degraded by small interfering RNA (siRNA) derived from double-stranded RNA (dsRNA) containing an identical or very similar nucleotide sequence to that of a target gene to be silenced. This process prevents the production of a protein encoded by the targeted gene through post-transcriptional, pre-translational manipulation. Accordingly, silencing of dominant disease genes or other target genes can be accomplished.

[0302] In vivo RNAi proceeds by a process in which the dsRNA is cleaved into short interfering RNAs (siRNAs) by an enzyme called Dicer, a dsRNA endoribonuclease, (Bernstein et al., 2001; Hamilton & Baulcombe, 1999, Science 286: 950; Meister and Tuschl, 2004, Nature 431, 343-9), thus producing multiple molecules from the original single dsRNA. siRNAs are loaded into the multimeric RNAi Silencing Complex (RISC) resulting in both catalytic activation and mRNA target specificity (Hannon and Rossi, Nature 431, 371-378, 2004; Novina and Sharp, Nature 430, 161-164, 2004). During siRNA loading into RISC, the antisense or guide strand is separated from the siRNA and remains docked in Argonaute-2 (Ago2), the RISC catalytic subunit (Leuschner et al., EMBO Rep. 7, 314-320, 2006). Certain cellular compartments, such as endoplasmic reticulum (ER), Golgi apparatus, ER-Golgi intermediate compartment (ERGIC), P-bodies, and early endosomes are enriched in Ago2. mRNAs exported from the nucleus into the cytoplasm are thought to pass through activated RISCs prior to ribosomal arrival, thereby allowing for directed, post-transcriptional, pre-translational regulation of gene expression. In theory, each and every cellular mRNA can be regulated by induction of a selective RNAi response.

[0303] The ability of siRNAs to efficiently induce an RNAi response in mammalian cells in vitro is known (Sontheimer, Nat. Rev. Mol. Cell. Biol. 6, 127-138, 2005). Typically, the IC.sub.50 for siRNAs is in the 10-100 pM range, significantly below the best drugs with IC.sub.50 values in the 1-10 nM range. Consequently, due to its exquisite selectivity, RNAi has become a corner-stone for directed manipulation of cellular phenotypes, mapping genetic pathways, discovering and validating therapeutic targets, and has significant therapeutic potential.

[0304] Aspects of RNAi include (1) dsRNA is the interfering agent; (2) the process can be sequence-specific and is remarkably potent (only a few dsRNA molecules per cell are required for effective interference); (3) the interfering activity (and presumably the dsRNA) can cause interference in cells and tissues far removed from the site of introduction. However, effective delivery of dsRNA is difficult. For example, a 21 bp dsRNA with a molecular weight of 13,860 Daltons cannot traverse the cell membrane to enter the cytoplasm, due to (1) the size and (2) the accumulation of negative charges on the RNA molecule at physiologically relevant pH levels. The methods and compositions of the invention provide the delivery of nucleotide constructs, such as dsRNA, into a cell through charge neutralization and improved uptake.

[0305] dsRNA including siRNA sequences that are complementary to a nucleotide sequence of the target gene can be prepared in any number of methods, e.g., those described herein. Methods and techniques for identifying siRNA sequences are known in the art. The siRNA nucleotide sequence can be obtained from the siRNA Selection Program, Whitehead Institute for Biomedical Research, Massachusetts Institute of Technology, Cambridge, Mass. (currently available at http:[//]jura.wi.mit.edu/bioc/siRNAext/; note that brackets have been added to remove hyperlinks) after supplying the Accession Number or GI number from the National Center for Biotechnology Information website (available on the World Wide Web at ncbi.nlm.nih.gov). Alternatively, dsRNA containing appropriate siRNA sequences can be ascertained using the strategy of Miyagishi and Taira (2003). Commercially available RNAi designer algorithms also exist (http:[//]rnaidesigner.invitrogen.com/rnaiexpress/). Preparation of RNA to order is commercially available.

[0306] Polynucleotide constructs of the invention may also act as miRNA to induce cleavage of mRNA. Alternatively, nucleotide constructs of the invention may act as antisense agents to bind to mRNA, either to induce cleavage by RNase or to sterically block translation.

[0307] Exemplary methods by which the nucleotide constructs of the invention can be transported into a cell are described herein.

Therapeutic Methods

[0308] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9)

[0309] PCSK9 is an enzyme encoded by PCSK9 gene in humans. This enzyme binds to the receptor for low-density lipoprotein particles (LDLR). LDLR binds and mediates cellular ingestion of LDL particles, thus reducing extracellular LDL particle concentration. After ingestion, LDLR is recycled back to the cell surface, where it can bind and mediate the ingestion of more LDL particles. When PCSK9 is bound to LDLR, upon ingestion of LDLR and LDL, LDLR is degraded and is not recycled back to the cell surface and is degraded instead. Reduction in the PCSK9 levels can thus lead to an increase in the LDLR recycling, thereby reducing the extracellular LDL particles concentration. Accordingly, PCSK9 has been targeted for the development of therapeutics for hypercholesterolemia.

[0310] The polynucleotide constructs disclosed herein having a sequence complementary to a portion of a PCSK9 transcript (e.g., a portion that is at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22) nucleotides long) may be used in a method of reducing low density lipoprotein levels in a subject in need thereof by administering an effective amount of the polynucleotide construct disclosed herein (e.g., a hybridized polynucleotide construct including a passenger strand and a guide strand containing a sequence complementary to a portion of a PCSK9 transcript) to the subject. PCSK9 gene and its transcripts are known in the art. The polynucleotide constructs disclosed herein having a sequence complementary to a portion of a PCSK9 transcript (e.g., to a portion that is at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22) nucleotides long) may also be used in a method of treating hypercholesterolemia by administering an effective amount of the polynucleotide construct disclosed herein (e.g., a hybridized polynucleotide construct including a passenger strand and a guide strand containing a sequence complementary to a portion of a PCSK9 transcript) to the subject.

[0311] Transthyretin (TTR)

[0312] Transthyretin (TTR) is a transport protein in the serum and cerebrospinal fluid that carries thyroxine and retinol-binding protein bound to retinol. TTR misfolding and aggregation is often associated with amyloid diseases (e.g., familial amyloid polyneuropathy and senile systemic amyloidosis). Accordingly, TTR has been targeted for the development of therapeutics for TTR-mediated amyloid diseases.

[0313] The polynucleotide constructs disclosed herein having a sequence complementary to a portion of a TTR transcript (e.g., to a portion that is at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22) nucleotides long) may be used in a method of reducing transthyretin levels in a subject in need thereof by administering an effective amount of the polynucleotide construct disclosed herein (e.g., a hybridized polynucleotide construct including a passenger strand and a guide strand containing a sequence complementary to a portion of a TTR transcript) to the subject. TTR gene and its transcripts are known in the art. The polynucleotide constructs disclosed herein having a sequence complementary to a portion of a TTR transcript (e.g., a portion that is at least 12 (e.g., 13, 14, 15, 16, 17, 18, 19, 20, 21, or 22) nucleotides long) may also be used in a method of treating hypercholesterolemia by administering an effective amount of the polynucleotide construct disclosed herein (e.g., a hybridized polynucleotide construct including a passenger strand and a guide strand containing a sequence complementary to a portion of a TTR transcript) to the subject.

[0314] The following examples are meant to illustrate the invention. They are not meant to limit the invention in any way.

EXAMPLES

Example 1. Synthesis and Purification of the Nucleotides and Polynucleotides of the Invention

[0315] ##STR00022##

[0316] To a solution of compound S1 (30.0 g, 168.5 mmol) in EtOH (120 mL) was added 30% hydrogen peroxide (50 mL) dropwise over 45 min (caution: exothermic). Reaction mixture became turbid with white precipitate. TLC showed completion of reaction at 3 hr, and the reaction mixture was diluted with water (300 mL) and carefully extracted with dichloromethane (200 mL3). The combined organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo to afford crude product. This was purified by flash silica gel column (220 g) chromatography using ISCO companion (ethyl acetate/hexane, 0-20% over 15 column volumes) to give 23.5 g (92%) of compound S2 as a light yellow oil which became solid on standing at room temperature. .sup.1H NMR (500 MHz, CDCl.sub.3): 7.34 (1H, dd, J 8.0 Hz), 7.31-7.28 (2H, m), 7.22 (1H, td, J 8.0, 1.0 Hz), 3.98 (2H, s).

##STR00023##

[0317] To an ice cold solution of LiAlH.sub.4 (7.4 g, 200 mmol) in diethyl ether (200 mL) was added dropwise a solution of compound S2 (15.0 g, 100 mmol) in diethyl ether over 1 h (caution: gas evolution and exothermic). The reaction mixture was allowed to reach room temperature, and stirring continued overnight. Reaction was carefully quenched with aq. Sodium sulfate until gas evolution stopped to give a white precipitate. To this 100 mL of 10% H.sub.2SO.sub.4 was carefully added and the organic layer separated. Aqueous layer extracted with 375 mL ether and the combined organic layers washed with water, brine, dried over sodium sulfate and evaporated to give compound S3 (14.6 g, 95%) as colorless oil which was used in the next reaction without further purification. .sup.1H NMR (500 MHz, CDCl.sub.3): 7.31 (1H, dd, J 7.5, 1.5 Hz), 7.20 (1H, dd, J 7.5, 1.5 Hz), 7.16-7.08 (2H, m), 3.91 (2H, t, J 6.5 Hz), 3.41 (1H, s), 2.98 (1H, J 6.5 Hz).

##STR00024##

[0318] To a solution of dithiodipyridine (52.0 g, 236.3 mmol) and acetic acid (3.0 mL) in methanol (200 mL) at room temperature was added a solution of compound S3 (14.6 g, 94.5 mmol) in methanol (50 mL) and stirred overnight. Volatiles were removed to produce a residue, to which 100 mL of diethyl ether were added, and the separated solids were filtered and washed with diethyl ether (350 mL). The combined ether washes were evaporated to give crude product, which, on flash silica gel column purification using ISCO companion (ethyl acetate/hexane, 0-50%), gave 14.1 g (57%) of compound S4. .sup.1H NMR (500 MHz, CDCl.sub.3): 8.48 (1H, d, J 5.0 Hz), 7.65-7.60 (3H, m), 7.25-7.18 (3H, m), 7.13-7.10 (1H, m), 3.96 (2H, t, J 6.5 Hz), 3.17 (1H, t, J 6.5 Hz).

##STR00025##

[0319] To a solution of compound S4 (4.5 g, 17.0 mmol) in 30.0 mL of dichloromethane at room temperature, MeOTf was added dropwise and stirred for 10 minutes followed by tert-butyl mercaptan (1.9 mL, 17.0 mmol) and N,N-diisopropylethylamine (6.0 mL, 34.0 mmol) addition. The reaction mixture was stirred for another 30 min at room temperature before being condensed in vacuo. The crude mixture was purified by silica gel column chromatography using ethyl acetate/hexane (0-30% gradient on Combi Flash Rf Instrument) to give product S5 as colorless oil (2.5 g, 61%). .sup.1H NMR (500 MHz): 7.84 (d, J 5.0 Hz, 1H), 7.25-7.13 (m, 3H), 3.92 (t, J 7.0 Hz, 2H), 3.12 (t, J 7.0 Hz, 2H), 1.30 (s, 9H).

##STR00026##

[0320] To a mixture of 2-methyl-2-mercaptopentanoic acid (S6, 0.74 g, 5.0 mmol) and acetic anhydride (0.52 mL, 5.5 mmol) in acetonitrile (10.0 mL) were added triethylamine (1.39 mL, 10.0 mmol) and DMAP (5 mg). The mixture was stirred for 1 hour, and propargylamine (0.69 g, 12.5 mmol) was added to the mixture, and stirring continued overnight. The volatiles were removed under vacuum to give a residue, which was subjected to flash silica gel column purification on an ISCO companion (ethyl acetate/hexane, 5-55%) to give 0.72 g (59%) of the title compound S7 as a white solid. .sup.1H NMR (500 MHz, CDCl.sub.3): 5.66 (1H, s), 4.06 (2H, dd, J 5.0, 2.5 Hz), 2.41-2.37 (2H, m), 2.23 (1H, t, J 2.5 Hz), 1.95-1.91 (2H, m), 1.39 (6H, s).

##STR00027##

[0321] To a solution of compound S4 (1.0 g, 3.8 mmol) in dichloromethane (12 mL) was added MeOTf (0.6 g, 3.8 mmol). The mixture was stirred for 15 min, at which time, S7 (0.57 g, 3.04 mmol) and N,N-diisopropylethylamine (1.0 mL) were added, and the resulting mixture was stirred for additional 30 min. Evaporation of the reaction mixture afforded a residue which was subjected to flash silica gel column chromatography on an ISCO companion (ethyl acetate/hexane 5-60% to give compound S8 (0.99 g, 78%) as a colorless oil. .sup.1H NMR (500 MHz, CDCl.sub.3): 57.83 (1H, d, J 8.0 Hz), 7.30-7.16 (3H, m), 5.05 (1H, s), 3.95 (2H, t, J 6.5 Hz), 3.88 (2H, dd, J 5.5, 2.5 Hz), 3.15 (2H, t, J 6.5 Hz), 2.23 (1H, t, J 2.5 Hz), 2.10-2.04 (2H, m), 1.83-1.79 (2H, m), 1.28 (6H, s).

Phosphoramidite Synthesis:

[0322] ##STR00028##

[0323] To a 78 C. solution of appropriately protected nucleoside (20.7 mmol) and N,N-diisopropylethylamine (22.7 mmol) in 100 mL of dry dichloromethane under argon, a solution of bis-(N,N-diisopropylamino)-chlorophosphine (22.7 mmol) in 20 mL of dichloromethane was slowly added. The reaction mixture was allowed to warm to room temperature over 1 hour while stirring was maintained. To this, a solution of appropriate alcohol (20.7 mmol) in 15 mL of dry dichloromethane was added, the resulting mixture was stirred for 10 minutes, at which time, 0.25M ETT in acetonitrile (12.42 mmol) was added dropwise. The reaction mixture was stirred for additional 16 hours at room temperature. The crude mixture was diluted with 200 mL of dichloromethane, washed sequentially with saturated NaHCO.sub.3 solution (50 mL) and brine (50 mL), and then dried over anhydrous Na.sub.2SO.sub.4. The volatiles were evaporated in vacuo, and the resulting mixture was purified by silica gel column chromatography using ethyl acetate/hexane (0-30% gradient on Combi Flash Rf Instrument) to give a diastereomeric mixture of phosphoramidite as a white powder.

##STR00029##

[0324] To a 78 C. solution of appropriate alcohol (7.46 mmol) and N,N-diisopropylethylamine (7.78 mmol) in dry dichloromethane (15 mL) under argon, a solution of bis-(N,N-diisopropylamino)-chlorophosphine (7.78 mmol) in dichloromethane (5.0 mL) was added. The reaction mixture was allowed to warm to room temperature over 1 hour, and the resulting solution was added dropwise to a dichloromethane (15 mL) suspension of appropriately protected nucleoside (3.73 mmol) and diisopropylammonium tetrazolide (7.46 mmol). The reaction continued for additional 16 hours at room temperature. The reaction mixture was diluted with 15 mL of dichloromethane, washed sequentially with saturated NaHCO.sub.3 solution (10 mL) and brine (10 mL), and then dried over anhydrous Na.sub.2SO.sub.4. The volatiles were evaporated in vacuo, and the mixture was purified by silica gel column chromatography using ethyl acetate/hexane (0-60% gradient on Combi Flash Rf Instrument) to give a diastereomeric mixture of phosphoramidite as a white powder.

[0325] The phosphoramidite monomers shown in Table 1 were synthesized using the standard synthetic procedures described herein.

TABLE-US-00001 TABLE 1 Compound # Structure .sup.31P NMR (, ppm) Synthesis Yield (%) U1 [00030] 154.73 (d, J 8.90 Hz) 154.52 (d, J 7.70 Hz) Method 1 45 U2 [00031] 149.30 (s) 149.05 (s) Method 1 41 U3 [00032] 154.75 (d, J 5.60 Hz) 154.36 (d, J 10.3 Hz) Method 1 21 U4 [00033] 154.98 (d, J 8.08 Hz) 154.74 (d, J 8.08 Hz) Method 1 54 U5 [00034] 154.84 (d, J 12.12 Hz) 154.50 (d, J 8.08 Hz) Method 1 53 U6 [00035] 154.6 (d, J 6.6 Hz) 154.5 (d, J 8.5 Hz) 154.2 (d, J 9.3 Hz) 152.8 (d, J 10.1 Hz) Method 1 60 U7 [00036] 155.27 (d, J 6.06 Hz) 155.05 (d, J 8.08 Hz) Method 1 50 U8 [00037] 155.17 (d, J 8.08 Hz) 154.67 (d, J 10.1 Hz) Method 1 48 U9 [00038] 155.83 (d, J 6.06 Hz) 155.34 (d, J 10.1 Hz) Method 1 55 U10 [00039] 155.4 (d, J 7.9 Hz) 154.7 (d, J 9.7 Hz) Method 1 54 C1 [00040] Method 1 C2 [00041] Method 1 C3 [00042] 154.80 (d, J 8.08 Hz) 154.71 (d, J 6.06 Hz) Method 1 51 C4 [00043] 155.18 (d, J 6.06 Hz) 154.79 (d, J 8.08 Hz) Method 1 55 C5 [00044] 151.9 (d, J 6.2 Hz) 151.2 (d, J 8.3 Hz) Method 1 28 C6 [00045] 149.3 (d, J 6.0 Hz) 149.1 (d, J 8.3 Hz) Method 1 35 C7 [00046] 149.4 (s) 149.1 (d, J 8.3 Hz) Method 1 21 C8 [00047] 149.7 (d, J 8.3 Hz) Method 1 36 C9 [00048] 150.2 (s) 150.0 (s) Method 1 27 C10 [00049] 150.6 (d, J 8.3 Hz) 150.1 (s) Method 1 37 C11 [00050] 149.7 (d, J 8.3 Hz) Method 1 41 C12 [00051] 149.9 (d, J 8.3 Hz) 149.6 (s) Method 1 48 C13 [00052] 149.6 (s) 149.5 (d, J 8.3 Hz) 149.1 (s) 147.8 (s) Method 1 37 C14 [00053] 150.2 (d, J 8.3 Hz) 149.8 (s) Method 1 14 C15 [00054] 150.2 (d, J 8.3 Hz) 150.1 (d, J 6.2 Hz) Method 1 48 C16 [00055] 150.2 (d, J 10.3 Hz) 149.8 (s) Method 1 47 C17 [00056] 150.9 (d, J 8.3 Hz) 150.6 (s) Method 1 52 C18 [00057] 150.2 (d, J 6.2 Hz) 149.9 (d, J 4.2 Hz) Method 1 41 C19 [00058] 150.0 (s) 149.5 (s) Method 1 10 C20 [00059] 149.3 (s) 148.8 (s) 147.6 (s) 146.7 (s) Method 1 4 C21 [00060] 149.80 (d, J 8.1 Hz) 149.55 (s) Method 1 47 C22 [00061] 150.46 (d, J 8.1 Hz) Method 1 22 A1 [00062] 154.80 (s) 154.0 (s) Method 1 40 A2 [00063] Method 1 A3 [00064] 154.79 (s) 154.01 (s) Method 1 34 A4 [00065] 155.85 (s) 155.09 (s) Method 1 25 A5 [00066] 154.81 (s) 153.99 (s) Method 1 55 A6 [00067] 150.24 (s) 149.63 (s) Method 1 39 A7 [00068] 155.20 (s) 154.60 (s) Method 1 56 A8 [00069] 155.4 (s) 154.0 (s) Method 1 80 G1 [00070] 150.63 (s) 149.20 (s) Method 1 36 G2 [00071] Method 2 G3 [00072] 154.91 (s) 154.36 (s) Method 2 55 G4 [00073] 155.29 (s) 154.85 (s) Method 2 29 G5 [00074] 154.94 (s) 154.05 (s) Method 2 18

Synthesis of Targeting Moieties

GalNAc (NAG) Targeting Moiety Synthesis:

[0326] ##STR00075##

[0327] Preparation of D-galactosamine pentaacetate (NAG2).

[0328] D-Galactosamine (25.0 g, 116 mmol) was suspended in anhydrous pyridine (250 mL) and cooled to 0 C. under an inert atmosphere. Acetic anhydride (120 mL, 1160 mmol) was added over the course of 2 h. After stirring overnight, the reaction mixture was concentrated in vacuo. Upon addition of methanol, a white solid precipitated and was collected via filtration to provide the desired product (42.1 g, 93% yield). .sup.1H NMR (CDCl.sub.3, 500 MHz): 5.69 (d, 1H, J 9.0 Hz), 5.40 (m, 1H), 5.37 (d, 1H, J 3.0 Hz), 5.08 (dd, 1H, J 3.0 Hz, 11 Hz), 4.44 (dt, 1H, J 9.5 Hz, 11 Hz), 4.17 (dd, 1H, J 7.0 Hz, 11.5 Hz), 4.11 (dd, 1H, J 7.0 Hz, 11.5 Hz), 4.01 (t, 1H, J 7.0 Hz), 2.17 (s, 3H), 2.13 (s, 3H), 2.05 (s, 3H), 2.02 (s, 3H), 1.94 (s, 3H), 1.57 (s, 3H).

[0329] Preparation of benzyl 5-hydroxy pentanoate (NAG5).

[0330] A solution of delta-valerolactone (10.0 g, 100 mmol) and NaOH (4.00 g, 100 mmol) in water (100 mL) was stirred overnight at 70 C. The reaction mixture was cooled to rt and concentrated in vacuo to give white solid NAG4. This solid was suspended in acetone (100 mL) and refluxed overnight with benzyl bromide (20.5 g, 120 mmol) and tetrabutylammonium bromide (1.61 g, 0.50 mmol). Acetone was removed in vacuo to afford an oily residue, which was dissolved in EtOAc and washed with sat NaHCO.sub.3(aq.) and brine. The organic layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuo give the oily product NAG5 (17.1 g, 82% yield). .sup.1H NMR (CDCl.sub.3, 500 MHz): 7.35 (m, 5H), 3.64 (q, 2H, J 6 Hz, 11.5 Hz), 2.41 (t, 2H, J 7.5 Hz), 1.75 (m, 2H), 1.60 (m, 2H), 1.44 (t, 1H, J 6 Hz).

[0331] Preparation of benzyloxycarbonylbutyl 2-deoxy 2-N-acetyl-3,4,6-tri-O-acetyl--D-galactopyranoside (NAG7)Method A.

[0332] Under an inert atmosphere, TMSOTf (8.56 g, 38.4 mmol) was added to a solution of NAG2 (10.0 g, 25.6 mmol) in DCE (100 mL) at ambient temperature. The mixture was stirred at 55 C. for 2 h, removed from heat, and stirred overnight. The reaction mixture was poured onto ice cold sat. NaHCO.sub.3(aq.) and extracted with CH.sub.2Cl.sub.2. The separated organic layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuo to give syrup NAG6. A solution NAG6 in DCE (60 mL) was charged with alcohol NAG5 (8.00 g, 38.4 mmol) and molecular sieves. The mixture was placed under an inert atmosphere, treated with TMSOTf (2.85 g, 12.8 mmol), and stirred overnight at room temperature. The mixture was poured over ice cold sat. NaHCO.sub.3 (aq.) and extracted with CH.sub.2Cl.sub.2. The organic layer was dried over Na.sub.2SO.sub.4 and concentrated in vacuo to give a crude material as syrup. This crude material was purified by SiO.sub.2 gel chromatography to afford glycoside NAG7 (3.3 g, 24% yield). .sup.1H NMR (CDCl.sub.3, 500 MHz): 7.35 (m, 5H), 5.98 (d, 1H, J 7.0 Hz), 5.57 (m, 1H), 5.34 (d, 1H, J 3.0 Hz), 5.25 (dd, 1H, J 3.0 Hz, 11 Hz), 5.10 (s, 2H), 4.63 (d, 1H, J 8.5 Hz), 4.11 (m, 2H), 3.95 (m, 1H), 3.88 (m, 2H), 3.49 (m, 1H), 2.37 (m, 2H), 2.13 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.90 (s, 3H), 1.70 (m, 2H), 1.61 (m, 2H).

[0333] Preparation of benzyloxycarbonylbutyl 2-deoxy 2-N-acetyl-3,4,6-tri-O-acetyl-3-D-galactopyranoside (NAG7)Method B.

[0334] To a solution of NAG2 (5.00 g, 12.8 mmol) and alcohol NAG5 (5.33 g, 25.6 mmol) in DCE (50 mL) was added Sc(OTf).sub.3 (0.44 g, 0.90 mmol) in one portion. The mixture was placed under an inert atmosphere and refluxed for 3 h. Upon cooling, the mixture was diluted with CH.sub.2Cl.sub.2, washed with sat NaHCO.sub.3(aq.), dried over MgSO.sub.4, and concentrated in vacuo. Purification by SiO.sub.2 gel chromatography afforded glycoside NAG7 (5.53 g, 80% yield).

[0335] Preparation of carboxybutyl 2-deoxy 2-N-acetyl-3,4,6-tri-O-acetyl-f-D-galactopyranoside (NAG8).

[0336] A solution of glycoside NAG7 (1.50 g, 2.41 mmol) in EtOH (25 mL) was degassed under vacuum and purged with Argon. The Palladium catalyst (10% wt. on activated carbon, 0.50 g) was added in one portion and the mixture was degassed under vacuum purged with argon. The heterogeneous mixture was charged with cyclohexene (25 mL) and refluxed for 6 h. Upon cooling, the catalyst was removed by filtration and the mother liquor concentrated in vacuo. The crude was purified by SiO.sub.2 gel chromatography to afford a white foam NAG8 (0.76 g, 70% yield). 1H NMR (CDCl.sub.3, 500 MHz): 5.72 (d, 1H, J 8.5 Hz), 5.35 (d, 1H, J 3.5 Hz), 5.26 (dd, 1H, J 3.5 Hz, 11.5 Hz), 4.67 (d, 1H, J 8.5 Hz), 4.17 (dd, 1H, J 6.5 Hz, 11.5 Hz), 4.12 (dd, 1H, 6.5 Hz, 11.5 Hz), 4.00 (dt, 1H, J 8.5 Hz, 11.5 Hz), 3.92 (m, 2H), 3.53 (m, 1H), 2.39 (m, 2H), 2.15 (s, 3H), 2.05 (s, 3H), 2.01 (s, 3H), 1.97 (s, 3H), 1.71 (m, 2H), 1.65 (m, 2H).

##STR00076##

[0337] Preparation of aminopropyl 6-hydrazinonicotamide acetone hydrazone (NAG11).

[0338] Boc 6-hydrazinonicotinic acid (520 mg, 2.1 mmol) in DCM (20 mL) was treated to EDCI (440 mg, 2.3 mmol), N-hydroxysuccinimide (NHS; 260 mg, 2.3 mmol), Boc-diamine (650 mg, 2.6 mmol), and DIEA (1.1 mL, 6.2 mmol) for 3 h. The reaction was concentrated in vacuo and purified by silica gel chromatography to afford NAG10 (364 mg, 43% yield). .sup.1H NMR (CDCl.sub.3, 500 MHz): 8.55 (br, 1H), 7.93 (d, 2H, J 7.5 Hz), 7.45 (br, 1H), 7.12 (br, 1H), 6.62 (d, 1H, J 8.5 Hz), 5.17 (br, 1H), 3.42 (m, 2H), 3.13 (m, 2H), 1.65 (m, 2H), 1.41 (s, 18H). The HyNic acetone hydrazone was formed through treatment of NAG10 (160 mg, 0.4 mmol) with TFA (9 mL) and acetone (1 mL) for 1 h. The reaction mixture was concentrated in vacuo and placed on the high vacuum to afford NAG11.

##STR00077## ##STR00078##

[0339] Preparation of tris-(carboxyethoxymethyl)-methylamido-dodecanedioate methyl ester (NAG14).

[0340] To a solution of dodecanedioic acid methyl ester (211 mg, 0.42 mmol) activated with HATU (122 mg, 0.50 mmol) and DIEA (218 L, 1.25 mmol) in DMF (2 mL) was added tris linker NAG12. After 1 h, the reaction mixture was concentrated in vacuo and purified by SiO.sub.2 gel chromatography to afford NAG13 (214 mg, 70% yield). MALDI-TOF mass calcd C.sub.38H.sub.69NO.sub.12: 731.48, Found: 755.10 [M+Na]. Tris t-butyl ester NAG13 was hydrolyzed with a TFA:TIPS:DCM (9:0.25:1) cocktail (10.25 mL) for 4 h and concentrated in vacuo to give tris acid NAG14. MALDI-TOF mass calcd C.sub.26H.sub.45NO.sub.12: 563.29, Found: 565.33 [M+H].

[0341] Preparation of tris-(aminopropamido-ethoxymethyl)-methylamido-dodecanedioate methyl ester (NAG16).

[0342] To a solution of tris acid NAG14 (230 mg, 0.41 mmol) activated with HATU (557 mg, 1.35 mmol) and DIEA (470 L, 2.70 mmol) in DMF (4 mL) was added monoBoc 1,3-diaminopropane (250 mg, 1.44 mmol). After 1 h, the reaction was concentrated in vacuo and purified by SiO.sub.2 gel chromatography to afford NAG15 (335 mg, 79% yield). MALDI-TOF mass calcd C.sub.50H.sub.93N.sub.7O.sub.15: 1031.67, Found: 1056.40 [M+Na]. Tris Boc linker NAG15 was treated with a TFA:TIPS:DCM (9:0.25:1) cocktail (10.25 mL) for 1 h and concentrated in vacuo to give tris amine NAG16. MALDI-TOF mass calcd C.sub.35H.sub.69N.sub.7O.sub.9: 731.51, Found: 733.18 [M+H].

[0343] Preparation of tris-Ga/NAc (NAG18):

[0344] Monosaccharide NAG8 (192 mg, 0.43 mmol) was treated with HATU (163 mg, 0.43 mmol) and DIEA (150 L, 0.86 mmol) in DMF (2 mL). After 30 min, a solution of NAG16 (80 mg, 0.11 mmol) in DMF (1 mL) was added and the mixture stirred for 1 h. The crude mixture was purified by SiO.sub.2 gel chromatography to afford NAG17 (82 mg, 37% yield). Mass calcd C.sub.92H.sub.150N.sub.10O.sub.39: 2019.00, Found: 2041.85 [M+Na]. The peracetylated trimer GalNAc (82 mg, 0.04 mmol) was hydrolyzed upon treatment with LiOH.H.sub.2O (34 mg, 0.81 mmol) in a THF:H.sub.2O (3:1) solution (8 mL) to afford NAG18. MALDI-TOF mass calcd C.sub.73H.sub.130N.sub.10O.sub.30: 1626.89, Found: 1634.52 [M+Li].

[0345] Preparation of HyNic trimer Ga/NAc (NAG19).

[0346] A solution GalNAc trimer NAG18 (32 mg, 0.02 mmol) and HyNic amine NAG11 (20.0 mg, 0.08 mmol) in DMF (1 mL) was treated with EDCI (16.2 mg, 0.08 mmol), NHS (2.5 mg, 0.02 mmol), and DIEA (28 L, 0.16 mmol) and stirred for 4 h. Upon concentration in vacuo, the crude was dissolved in DMSO and purified by RP-HPLC to afford NAG19 (12.6 mg, 35% yield). MALDI-TOF mass calcd C.sub.85H.sub.147N.sub.15O.sub.30: 1858.04, Found: 1859.83 [M+H].

##STR00079##

[0347] Preparation of azido-PEG3-trimer Ga/NAc (NAG21).

[0348] GalNAc trimer carboxylic acid NAG18 (60 mg, 0.03 mmol), azido-PEG3-amine NAG20 (45.6 mg, 0.21 mmol), TBTU (23.8 mg, 0.07 mmol), HOBt (11.5 mg, 0.03 mmol), and DIEA (34 L) were dissolved in DMSO (0.5 mL) and stirred 2 h. The base was removed in vacuo and the crude purified by RP-HPLC to afford NAG21 (24 mg, 44%). AP-ESI+ Mass calcd C.sub.81H.sub.146N.sub.14O.sub.32: 1827.02, Found: 914.8 [M+2H].sup.2+.

##STR00080##

[0349] Preparation of 1-bromo 2-deoxy-2-acetamido 3,4,6-tri-O-acetyl-Pi-D-galactopyranoside (NAG22).

[0350] To a D-galactosamine pentaacetate (NAG2, 10.0 g, 1 eq, 25.8 mmol) suspension in DCM (90 mL) at 0 C. in an ice bath under an argon balloon was added bromotrimethylsilane (4.1 mL, 1.2 eq, 31 mmol) drop wise with stirring. Ice bath was removed after 10 minutes and the reaction was allowed to stir at room temperature overnight. Reaction was checked by TLC (Hanessians Stain) in 75% hexanes:ethyl acetate. Reaction was concentrated in vacuo, azeotroped with cyclohexane (350 mL). Dried on high vacuum overnight and used as is.

[0351] Preparation of 1-azido 2-deoxy-2-acetamido 3,4,6-tri-O-acetyl--D-galactopyranoside (NAG23).

[0352] NAG22 (10.6 g, 1.0 eq, 25.8 mmol) was dissolved in DCM (100 mL). To this solution was added sodium azide (4.86 g, 2.9 eq, 74.8 mmol) in water (100 mL) and tetrabutylammonium bisulfate (8.32 g, 0.95 eq, 24.5 mmol). The reaction mixture was stirred vigorously for 1 hour. Reaction was checked by TLC (Hanessians Stain) in 75% Hexanes:Ethyl Acetate. Reaction was extracted with DCM (250 mL). The organic layer was dried over anhydrous MgSO.sub.4 and concentrated in vacuo. The material was then purified by silica gel flash chromatography (3:1 Hexanes:Ethyl acetate). Proton NMR of the material collected was consistent with the published structure. M+H=373.0

[0353] Preparation of 1-amino 2-acetamido 1,2-dideoxy 3,4,6-tri-O-acetyl--D-galactopyranose (NAG24).

[0354] To NAG23 (0.26 g, 1 eq, 0.7 mmol) dissolved in ethyl acetate (25 mL) was added palladium on carbon (26 mg). Next a hydrogen balloon and vacuum line were inserted. The reaction was evacuated 3 and purged with hydrogen after each evacuation. Reaction was stirred at room temperature for 1 hour. LC/MS after 1 hour confirmed the formation of the product. Reaction was filtered over a bed of celite. Wash the celite 310 mL of EtOAc. Reaction was concentrated in vacuo and used in the next step as is. M+H=346.6

[0355] Preparation of 1-amino (15-azido-tetraethyleneglycol propanoyl) 2-acetamido 1,2-dideoxy--D-galactopyranoside (NAG26).

[0356] To NAG24 (0.24 g, 1 eq, 0.7 mmol) dissolved in ethyl acetate (45 mL) and DIEA (0.24 mL, 2 eq, 1.4 mmol) was added azido-PEG4-NHS (0.41 g, 1.5 eq, 1.05 mmol) in ethyl acetate (5 mL) drop wise with stirring under an argon balloon. The reaction was allowed to stir at room temperature overnight. Completion of the reaction was verified by LC/MS. M+H=619.5. Ethyl acetate was removed in vacuo and use as is in the next step. To NAG 25 (0.43 g, 1 eq, 0.7 mmol) dissolved in MeOH (10 mL) was added 100 L of a 25% sodium methoxide solution in methanol. Reaction stirred at room temperature for 1 hour under argon balloon. LC/MS after 1 hour showed only starting material. Added 500 L of a 25% sodium methoxide solution in methanol. LC/MS after 1 hour showed formation of product and disappearance of starting material. Dowex resin was added until pH of solution reached 7. The resin was removed Filter off resin, remove solvent in vacuo and purify by reverse phase HPLC. M+H=493.7.

##STR00081##

[0357] Preparation of [5-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}ethylamino)-5-oxopentanoyl] 2-deoxy 2-N-acetyl-3,4,6-tri-O-acetyl--D-galactopyranoside (NAG27).

[0358] To a solution of NAG8 (1.00 g, 2.24 mmol) in THF (8 mL) was added DIC (0.56 g, 4.48 mmol) and HOBt (0.25 g, 2.17 mmol). After 1 h, white precipitate had formed and the reaction was cooled to 0 C. A solution azido-PEG3-amine (0.63 g, 2.91 mmol) in THF (2 mL) was added and the reaction was stirred for an additional 1 h. RP-HPLCMS showed formation of the desired NAG27. ESI MS+ mass calculated C.sub.27H.sub.45N.sub.5O.sub.13: 647.7, Found: 647.8 [M+H]. The precipitate was removed by filtration and the reaction concentrated in vacuo to give thick syrup.

[0359] Preparation of [5-(2-{2-[2-(2-azidoethoxy)ethoxy]ethoxy}ethylamino)-5-oxopentanoyl] 2-deoxy 2-N-acetyl --D-galactopyranoside (NAG28).

[0360] Crude NAG27 was dissolved in anhydrous methanol (10 mL) and treated with NaOMe in MeOH (25 wt %, 250 L). The reaction was stirred overnight at room temperature. After which, RP-HPLCMS showed consumption of NAG27 and formation of the NAG28. ESI MS+ mass calculated C.sub.21H.sub.31N.sub.5O.sub.10: 521.6, Found: 522.3 [M+H]. Dowex H+ resin was added to neutralize the base, the resin was removed by filtration, and the liquor was concentrated in vacuo. Crude NAG28 was purified by RP-HPLC to afford 0.42 g, 36% yield over two steps.

[0361] Preparation of ([3-(tert-butoxycarbonylamino)propylamino])-5-oxopentanoyl] 2-deoxy 2-N-acetyl-3,4,6-tri-O-acetyl--D-galactopyranoside (NAG29).

[0362] To a solution of NAG8 (0.29 g, 0.65 mmol) in DMF (3 mL) was activated with HATU (0.25 g, 0.65 mmol) and DIEA (0.34 mL, 1.95 mmol). After 10 min, NH-Boc 1,3-diaminopropane (0.13 g, 0.72 mmol) was added and stirred for 2 h. The mixture was concentrated in vacuo and purified by SiO.sub.2 chromatography to provide NAG29 (0.30 g, 77% yield). ESI MS+ mass calculated C.sub.27H.sub.45N.sub.3O.sub.12: 603.7, Found: 626.8 [M+Na].

[0363] Preparation of ([3-(amino)propylamino])-5-oxopentanoyl] 2-deoxy 2-N-acetyl--D-galactopyranoside (NAG31).

[0364] A solution of NAG29 (0.30 g, 0.50 mmol) in anhydrous methanol was treated with NaOMe in MeOH (25 wt %, 50 L). After 20 min, TLC showed complete consumption of NAG29. Dowex strong H+ resin was added to acidify the reaction and stirred for 30 min. The resin was filtered off and washed with 1% TEA in MeOH and 1M NaOH (aq). The filtrate was neutralized with 1M HCl (aq) and concentrated in vacuo to give NAG31 (0.052 g, 28% yield). ESI MS+ mass calculated C.sub.16H.sub.31N.sub.3O.sub.7: 377.4, Found: 377.6 [M+H].

[0365] Preparation of ({3-[6-(isopropylidenehydrazino)-nicotinoylamino]propylamino}-5-oxopentanoyl) 2-deoxy 2-N-acetyl--D-galactopyranoside (NAG32).

[0366] A solution NAG31 (0.009 g, 22 umol) in DMSO (1 mL) was treated with HyNic-sulfo-NHS (0.007 g, 18 umol) and DIEA (9.4 L, 54 umol) for 1 h and purified by RP-HPLC to afford NAG32 TFA salt (0.010 g, 68% yield). ESI MS+ mass calculated C.sub.25H.sub.40N.sub.6O.sub.8: 552.6, Found: 554.0 [M+H].

##STR00082##

[0367] Preparation of 1-amino-(15-azido-diethyleneglycol propranoyl) 2-acetamido 1,2-dideoxy 3,4,6-tetra-O-acetyl--D-galactopyranoside (NAG33).

[0368] To NAG24 (2.3 g, 6.7 mmol) dissolved in ethyl acetate (90 mL) and DIEA (1.7 mL, 9.9 mmol) was added azido-PEG2-NHS (1.0 g, 3.3 mol) in ethyl acetate (10 mL) drop wise with stirring under an argon balloon. The reaction was allowed to stir at room temperature overnight. Completion of the reaction was verified by LC/MS. ESI MS+. The crude product was purified by RP-HPLC to afford NAG33 (1.2 g). Mass calcd C.sub.21H.sub.33N.sub.5O.sub.11: 531.22, Found: 532.3 [M+H]+.

[0369] Preparation of 1-amino-[2-(2-aminoethoxy)ethoxy]propionyl] 2-acetamido 1,2-dideoxy 3,4,6-tetra-O-acetyl f-D-galactopyranose (NAG34).

[0370] To NAG33 (1.2 g, 2.3 mmol) dissolved in ethyl acetate (25 mL) was added palladium (10% Pd on activated carbon, 122 mg). Next a hydrogen balloon and vacuum line were inserted. The reaction was evacuated and purged with hydrogen gas (3 cycles). After stirring at room temperature for 1 hour, RP-HPLC/MS confirmed the formation of the product. Reaction was filtered over a bed of celite and washed with EtOAc (310 mL). Concentration in vacuo afforded in quantitative yield. ESI MS+ Mass calcd C.sub.21H.sub.35N.sub.3O.sub.11: 505.23, Found: 506.3 [M+H].sup.+.

[0371] Preparation of peracetylated azido PEG2 N-GalNAc trimer (NAG36).

[0372] To tri-acid linker M13 (52.5 mg, 0.07 mmol), DIEA (73.2 L, 0.42 mmol) in DMF (2 mL) was added HATU (119.8 mg, 0.32 mmol) in DMF (2 mL). The reaction was allowed to stir for 10 minutes at room temperature. Next NAG34 (159 mg, 0.32 mmol) in DMF (1 mL) was added, and the mixture was stirred overnight at room temperature. LC/MS after 18 hour confirmed the formation of the product. Water (10 mL) was added, and the resulting mixture was washed with DCM (35 mL). The separated organic layers were dried over Na.sub.2SO.sub.4, filtered, and concentrated in vacuo to afford NAG35 (155 mg), ESI MS+ mass calcd C.sub.96H.sub.158N.sub.14O.sub.44: 2210.5, Found: 1106.8 [M+2H].sup.2+. To a solution of NAG35 (155 mg, 70 mol) in MeOH (5 mL) was added sodium methoxide (25% wt MeOH, 100 L). The reaction mixture was stirred at room temperature for 1 hour under argon balloon. LC/MS after 1 hour showed product formation and disappearance of starting material. Dowex H+ strongly acidic resin was added to neutralize the reaction. The resulting mixture was filtered to remove resin, and the filtrate was concentrated in vacuo to give a crude product, which, upon purification by reverse phase HPLC, afforded NAG36 (10 mg). ESI MS+ Mass calcd C.sub.78H.sub.140N.sub.14O.sub.35: 1832.96, Found: 917.7 [M+2H].sup.2+.

[0373] Compounds NAG37, NAG38, and NAG39 were prepared in a manner similar to the synthesis of NAG26.

##STR00083##

TABLE-US-00002 TABLE 2 Compound # Peg-X Molecular formula MS calc MS found (ESI+) NAG37 2 C.sub.15H.sub.27N.sub.5O.sub.8 405.4 406.2 NAG26 4 C.sub.19H.sub.35N.sub.5O.sub.10 493.5 493.7 NAG38 6 C.sub.23H.sub.43N.sub.5O.sub.12 581.6 581.8 NAG39 8 C.sub.27H.sub.51N.sub.5O.sub.14 669.7 670

Phosphotriester Oligonucleotide Synthesis:

General Scheme:

[0374] ##STR00084##

Experimental Details:

[0375] All the oligonucleotide sequences synthesized were modified at 2-ribose sugar position with 2-F and 2-OMe modifications to improve serum stability and to minimize off-target effects. Automated oligonucleotide synthesis (1 mol scale) was carried out with the following reagents/solvents: [0376] Oxidizer0.02 M I.sub.2 in THF/pyridine/H.sub.2O (60 s oxidation per cycle) [0377] Deblocking agent3% trichloroacetic acid (240 s deblocks per cycle) [0378] Cap Mix ATHF/pyridine/Pac.sub.2O (60 s capping per cycle) [0379] Cap Mix B16% methyl imidazole in THF (60 s capping per cycle) [0380] Sulfurization0.05 M sulfurizing Reagent 3-((N,N-dimethylaminomethylidene)amino)-3H-1,2,4-dithiazole-5-thione, DDTT in 60% pyridine/40% acetonitrile (360 s sulfurization per cycle)
Exceptions to standard oligonucleotide synthesis conditions were as follows: [0381] Controlled Pore Glass (CPG) supports with Q-linkers (hydroquinone-O,O-diacetic acid linker arm) for milder deprotection were used [0382] All disulfide phosphoramidites were resuspended to 100 mM in 100% anhydrous acetonitrile prior to synthesis [0383] Phosphoramidite activation was performed with 2.5-fold molar excess of 5-benzylthio-1-H-tetrazole (BTT). Activated phosphoramidites were coupled for 23 minute coupling steps per insertion.

Oligonucleotide Deprotection & Purification Protocol:

[0384] Following automated oligonucleotide synthesis, phosphotriester oligonucleotides were cleaved and deprotected in 1 mL of 10% diisopropylamine in methanol (10% DIA/MeOH) for 4 h at room temperature. Following the 4 h deprotection, oligo samples were dried by centrifugal evaporation.

[0385] Oligo synthesis using phosphoramidite monomers having standard protecting groups (such as A-Bz, CAc and G-iBu etc.), phosphotriester oligonucleotides were cleaved and deprotected in 1.0 mL of AMA (1:1 ratio of 36% aq. ammonia and 40% methylamine in methanol) for 2 h at room temperature followed by centrifugal evaporation.

[0386] Crude oligo pellets were resuspended in 100 L of 50% acetonitrile briefly heated to 65 C., and vortexed thoroughly. Total 100 L crude oligo samples were injected onto RP-HPLC with the following buffers/gradient: [0387] Buffer A=50 mM TEAA in Water [0388] Buffer B=90% Acetonitrile [0389] Flow Rate=1 mL/min [0390] Gradient: [0391] 0-2 min (100% Buffer A/0% Buffer B) [0392] 2-42 min (0% to 60% Buffer B) [0393] 42-55 min (60% to 100% Buffer B) [0394] Across the dominant RP-HPLC peaks, 0.5 mL fractions were collected and analyzed by MALDI-TOF mass spectrometry to confirm presence of desired mass. Purified fractions containing correct mass were frozen and lyophilized. Once dry, fractions were resuspended, combined with corresponding fractions, frozen and lyophilized for final product.

[0395] Triester insertions requiring additional deprotection were initially isolated as described above followed by the necessary secondary deprotection steps (see below):

Secondary Deprotection of Phosphotriester Oligonucleotide Having Acetal Group:

[0396] RP-HPLC purified oligo products were resuspended in 100 L of 80% formic acid. Reaction was allowed to proceed at room temperature for 1 h per aldehyde modification. Reaction was monitored by MALDI-TOF mass spectrometry to confirm complete deprotection. Once deprotection was complete, samples were frozen and lyophilized until dry. Lyophilized samples were then resuspended in 1 mL of 20% acetonitrile and gel-filtered for isolation of final oligo product.

Secondary Deprotection of Phosphotriester Oligonucleotide Having TBDMS Protection:

[0397] RP-HPLC purified oligo products were resuspended in 219 L of anhydrous DMSO, heated briefly to 65 C., and vortexed thoroughly. To the DMSO solution, 31 L of 6.1 M triethylamine trihydrofluoride (TEA.3HF) was added to give a final concentration of 0.75 M. Reaction was allowed to proceed at room temperature for 1 h per TBDMS-protected hydroxyl modification. Reaction was monitored by MALDI-TOF mass spectrometry to confirm complete deprotection. Once deprotection was complete, 35 L of 3 M sodium acetate followed by 1 mL of butanol were added. Samples were vortexed thoroughly and placed at 80 C. for 2 h. After 2 h, samples were centrifuged to pellet oligonucleotides. Butanol layer was removed, and the oligo pellet was resuspended in 1 mL of 20% acetonitrile. Samples were gel-filtered for isolation of final oligo product.

Conjugation Methods

Click Reaction:

CopperTHPTA Complex Preparation:

[0398] A 5 mM aqueous solution of copper sulfate pentahydrate (CuSO.sub.4.5H.sub.2O) and a 10 mM aqueous solution of tris(3-hydroxypropyltriazolylmethyl)amine (THPTA) were mixed 1:1 (v/v) (1:2 molar ratio) and allowed to stand at room temperature for 1 hour. This complex can be used to catalyze Huisgen cycloaddition for example See General Conjugation Schemes 1-6.

General Procedure (100 nM Scale):

[0399] To a solution of 710 L of water and 100 L tert-butanol (10% of final volume) in a 1.7 mL Eppendorf tube was added 60 L of the copper-THPTA complex followed by 50 L of a 2 mM solution of the oligo, 60 L of a 20 mM aqueous sodium ascorbate solution and 20 L of a 10 mM solution of GalNAc-azide. After thorough mixing the solution was allowed to stand at room temperature for 1 hour. Completion of the reaction was confirmed by gel analysis.

[0400] The reaction mixture is added to a screw cap vial containing 5-10 fold molar excess of SiliaMetS TAAcONa (resin bound EDTA sodium salt). The mixture is stirred for 1 hour. This mixture is then eluted through an IllustraNap-10 column Sephadex. The solution is then frozen and lyophilized overnight.

General Conjugation Scheme 1:

[0401] ##STR00085##

General Conjugation Scheme 2:

[0402] ##STR00086##

General Conjugation Scheme 3:

[0403] ##STR00087##

General Conjugation Scheme 4:

[0404] ##STR00088##

General Conjugation Scheme 5:

[0405] ##STR00089##

General Conjugation Scheme 6:

[0406] ##STR00090##

General Conjugation Scheme 7:

[0407] ##STR00091##

[0408] In general conjugation scheme 7, the conjugation product contains one and only one AM and one and only one oligonucleotide.

[0409] The conjugation schemes described herein are also applicable to non-bioreversible groups and differ from those showing bioreversible groups in that the non-bioreversible groups do not include the disulfide.

TABLE-US-00003 TABLE3 Compound SEQID Conjugation # Ligand Target NO: Strand Sequences(5-3) Linker SB-0097 NAG21 ApoB 1 P UCaUCaCaCUgaaUaCCaaUt Alkyne-Disulfide(ortho) 2 G UUggUaUUCagUgUgaUgaUt SB-0206 NAG21 AT3 3 P gpgUuAaCaCCAuUuAcUuCaa Homopropargyl 4 G UUgAaGuAaAuggUgUuAaCcag SB-0209 NAG21 AT3 5 P GsgsUuAaCaCCAuUuAcUuCaA-Alk 3 Alkyne 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0823 NAG36 AT3 3 P gpgUuAaCaCCAuLhaAcUuCama Homopropargyl 4 G UUgAaGuAaAuggUgUuAaCcamg SB-0824 NAG36 AT3 3 P gpgUuAaCaCCAuLhaAcUuCaBa Homopropargyl 4 G UUgAaGuAaAuggUgUuAaCcaBg SB-0825 NAG36 AT3 58 P gpgUuAaCaCCAuLhaAcUuCaMa Homopropargyl 59 G UUgAaGuAaAuggUgUuAaCcaMg SB-0826 NAG36 AT3 3 P gpgUuAaCaCCAuLhaAcUuCaa Homopropargyl 4 G UUgAaGuAaAuggUgUuAaCcag SB-0827 NAG21 ApoB 7 P UpCaUCaCaCUgaaUaCCaaUt Homopropargyl 8 G UUgGuAuUcAgUgUgAuGaUt SB-0828 NAG36 ApoB 7 P UpCaUCaCaCUgaaUaCCaaUt Homopropargyl 8 G UUgGuAuUcAgUgUgAuGaUt SB-0829 NAG36 ApoB 7 P UpCaUCaCaCUgaaUaCCaaumt Homopropargyl 9 G UUggUaUUCagUgUgaUgaumt SB-0830 NAG21 ApoB 1 P UCaUCaCaCUgaaUaCCaaUt Alkyne-Disulfide(ortho) 8 G UUgGuAuUcAgUgUgAuGaUt SB-0875 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCsasa 11 G UUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0876 NAG21 AT3 10 P gsgUuAaCaCCAuUuAcUuCasa 11 G UUgAaGuAaAuggUgUuAaCcasg Alkyne-Disulfide(ortho) SB-0877 NAG21 AT3 12 P GsgsUuAaCaCCAuUuAcUuCsasA 11 G UUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0884 NAG21 AT3 3 P gpgUuAaCaCCAuUuAcUuCaa Homopropargyl 13 G uUgAaGuAaAuggUgUuAaCcag SB-0886 NAG21 AT3 3 P gpgUuAaCaCCAuUuAcUuCaa Homopropargyl 13 G uUgAaGuAaAuggUgUuAaCcag SB-0887 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0888 NAG21 AT3 12 P GsgsUuAaCaCCAuUuAcUuCapA Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0889 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCsasa 14 G UUgAaGuAaAuggugUuAaCcsasg Alkyne-Disulfide(ortho) SB-0894 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCaa 14 G UUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0895 NAG21 AT3 15 P GsgsUuAaCaCCAuUuAcUuCaa 14 G UUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0896 NAG21 AT3 16 P gsgsUuAaCaCCAuUuaCuUcapa Homopropargyl 17 G usUsGaAguAaAuggUgUuAaccsasg SB-0897 NAG21 AT3 16 P gpgUuAaCaCCAuUuaCuUcaa Homopropargyl 17 G uUGaAguAaAuggUgUuAaccag SB-0898 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 18 G uUgAaGuAaAuggUgUuAaCcsasgtt SB-0899 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 18 G uUgAaGuAaAuggUgUuAaCcsasgtst SB-0900 NAG21 AT3 16 P gsgsUuAaCaCCAuUuaCuUcapa Homopropargyl 19 G uUGaAguAaAuggUgUuAaccsasgtt SB-0901 NAG21 AT3 16 P gsgsUuAaCaCCAuUuaCuUcapa Homopropargyl 19 G uUGaAguAaAuggUgUuAaccsasgtst SB-0902 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 18 G uUgAaGuAaAuggUgUuAaCcsasgstst SB-0922 NAG21 AT3 20 P UpgGuAuCaGCCaAcCgCcUuU Homopropargyl 21 G aAaGgCgGuUggcUgAuAcCaac SB-0923 NAG21 AT3 22 P apuCgAaAaGCCaAcAaGuCCU Homopropargyl 23 G aGgAcUuGuUggcUuUuCgAuag SB-0924 NAG21 AT3 24 P gpgUuAaCaCCAuUuAcUuCaa-C3 Homopropargyl 13 G uUgAaGuAaAuggUgUuAaCcag SB-0925 NAG21 AT3 3 P gpgUuAaCaCCAuUuAcUuCaa Homopropargyl 13 G uUgAaGuAaAuggUgUuAaCcag-C3 SB-0926 NAG21 AT3 24 P gpgUuAaCaCCAuUuAcUuCaa-C3 Homopropargyl 13 G uUgAaGuAaAuggUgUuAaCcag-C3 SB-0927 NAG21 AT3 24 P gsgsUuAaCaCCAuUuAcUuCsasa-C3 14 G uUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0928 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCsasa 13 G uUgAaGuAaAuggUgUuAaCcsasg-C3 Alkyne-Disulfide(ortho) SB-0929 NAG21 AT3 24 P gsgsUuAaCaCCAuUuAcUuCsasa-C3 13 G uUgAaGuAaAuggUgUuAaCcsasg-C3 Alkyne-Disulfide(ortho) SB-0930 NAG26 AT3 10 P qpgpUpuAaCaCCAuUuAcUuCaa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0931 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 13 G uUgAaGuAaAuggUgUuAaCcag SB-0932 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0933 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa-C3 Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0934 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsasg-C3 SB-0935 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa-C3 Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsasg-C3 SB-0936 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsasgs-C3 SB-0937 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G C3-usUsgAaGuAaAuggUgUuAaCcsasg SB-0938 NAG26 AT3 24 P gsgsUuAaCaCCAuUuAcUuCpapa Homopropargyl 14 G uUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0939 NAG26 AT3 24 P gsgsUuAaCaCCAuUuAcUuCpapa-C3 Homopropargyl 14 G uUgAaGuAaAuggUgUuAaCcsasg Alkyne-Disulfide(ortho) SB-0940 NAG26 AT3 24 P gsgsUuAaCaCCAuUuAcUuCpapa Homopropargyl 14 G uUgAaGuAaAuggUgUuAaCcsasg-C3 Alkyne-Disulfide(ortho) SB-0941 NAG26 AT3 24 P gsgsUuAaCaCCAuUuAcUuCpapa-C3 Homopropargyl 14 G uUgAaGuAaAuggUgUuAaCcsasg-C3 Alkyne-Disulfide(ortho) SB-0952 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUbsgAaGuAaAuggUgUuAaCcsasg SB-0953 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAabGuAaAuggUgUuAaCcsasg SB-0954 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 26 G usUsgAaGuAaAuggUgUUbAaCcsasg SB-0962 NAG26 AT3 27 P GsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0963 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Alkyne-Disulfide(ortho); Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0964 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACUUCapa Alkyne-Disulfide(ortho); Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0965 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACUUCaa Alkyne-Disulfide(ortho) 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0966 NAG26 AT3 25 P gsgsUbuAaCaCCAuUuACUUCaa Alkyne-Disulfide(ortho) 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0967 NAG26 AT3 24 P gpgpUpuAaCaCCAuUuAcUuCsasa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0968 NAG21 AT3 28 P gLscLsaststsgsgstsaststLscLsaLs- Homopropargyl S-S-GsgsUuAaCaCCAuUuAcUuCapA 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0969 NAG21 AT3 29 P usascsasasas-S-S- Homopropargyl GsgsUuAaCaCCAuUuAcUuCapA 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-0970 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUpsgAaGuAaAuggUgUuAaCcsasg SB-0971 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgpAaGuAaAuggUgUuAaCcsasg SB-0972 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 30 G usUsgapaGuAaAuggUgUuAaCcsasg SB-0973 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAapGuAaAuggUgUuAaCcsasg SB-0974 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 26 G usUsgAaGuAaAuggUgUUpAaCcsasg SB-0975 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 31 G usUsgAaGuAaAuggUgUuapaCcsasg SB-0976 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAapCcsasg SB-0977 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCpcsasg SB-0978 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcspasg SB-0979 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsaspg SB-0991 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 26 G usUsgAaGuAaAuggUgUUpAaCcsasg SB-0992 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 31 G usUsgAaGuAaAuggUgUuapaCcsasg SB-0993 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAapCcsasg SB-0994 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCpcsasg SB-0995 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcspasg SB-0996 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsaspg SB-1010 NAG21 C5 32 P AsasGcAaGaUAUuUuUaUaAUpA Homopropargyl 33 G usAsuUaUaAaAauaUcUuGcUususu SB-1011 NAG21 C5 34 P apaGcAaGaUAUuUuUaUaAUA Homopropargyl 33 G uAuUaUaAaAauaUcUuGcUuuu SB-1012 NAG21 C5 35 P asasGcAaGaUAUuUuuAuAaUpa Homopropargyl 36 G usAsUuAuaAaAauaUcUuGcuususu SB-1013 NAG21 C5 35 P apaGcAaGaUAUuUuuAuAaUa Homopropargyl 36 G uAUuAuaAaAauaUcUuGcuuuu SB-1031 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCpcsasg SB-1057 NAG21 C5 35 P asasGcAaGaUAUuUuuAuAaUpa Homopropargyl 36 G usAsUuAuaAaAauaUcUuGcupususu SB-1058 NAG36 C5 35 P asasGcAaGaUAUuUuuAuAaUpa Homopropargyl 36 G usAsUuAuaAaAauaUcUuGcupususu SB-1059 NAG26 C5 37 P asasGcAaGaUAUuUuuapuapaUpa Homopropargyl 36 G usAsUuAuaAaAauaUcUuGcuususu SB-1060 NAG26 C5 37 P asasGcAaGaUAUuUuuapuapaUpa Homopropargyl 36 G usAsUuAuaAaAauaUcUuGcupususu SB-1091 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCbcsasg SB-1092 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1093 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1094 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaChcsasg SB-1095 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCdcsasg SB-1096 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaC(Hex)csasg SB-1097 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaC(Hexe)csasg SB-1098 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCncsasg SB-1099 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCPcsasg SB-1214 NAG36 AT3 5 P GsgsUuAaCaCCAuUuAcUuCaA-Alk 3 Alkyne 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1215 NAG36 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1216 NAG28 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1232 NAG21 AT3 16 P gsgsUuAaCaCCAuUuaCsuUscapa Homopropargyl 25 G usUsGaAguAaAuggUgUuAaccsasg SB-1250 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 38 G usUsgAaGuAaAuggUgUuAaccsasg SB-1251 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 31 G usUsgAaGuAaAuggUgUuaaCcsasg SB-1252 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 39 G usUsgAaGuAaAuggUgUuaaccsasg SB-1253 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCscsasg SB-1254 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAsaCcsasg SB-1255 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAsaCscsasg SB-1256 NAG21 AT3 10 P gsgsUuAaCaCCAuUuAcUuCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuApaCpcsasg SB-1276 NAG21 TTR 40 P AsasCaGuGuUCUuGcUcUaUapA Homopropargyl 41 G usUsaUaGaGcAagaAcAcUgUususU SB-1277 NAG21 TTR 40 P AsasCaGuGuUCUuGcUcUaUapA Homopropargyl 41 G usUsaUaGaGcAagaAcAcUgUpususU SB-1278 NAG26 TTR 42 P AsasCaGuGuUCUuGcUCpUapUapA Homopropargyl 41 G usUsaUaGaGcAagaAcAcUgUususU SB-1279 NAG26 TTR 42 P AsasCaGuGuUCUuGcUCpUapUapA Homopropargyl 41 G usUsaUaGaGcAagaAcAcUgUpususU SB-1284 NAG26 AT3 43 P gsgsUuAaCaCCAuUUpACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1285 NAG26 AT3 44 P gsgsUuAaCaCCAUpUUpACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1286 NAG26 AT3 44 P gsgsUuAaCaCCAUUUACpUUpCapa Alkyne-Disulfide(ortho); Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1289 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAasCcsasg SB-1290 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCscsasg SB-1291 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAsaCscsasg SB-1292 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuApaCpcsasg SB-1293 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 31 G usUsgAaGuAaAuggUgUuaaCcsasg SB-1294 NAG21 AT3 45 P gsgsUuAaCaCCAuUuAcUUbCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1295 NAG21 AT3 46 P gsgsUuAaCaCCAuUuACbUUbCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1296 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= 4-Pentyn-2-yl Phosphotriester SB-1297 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= 2-Methyl-Propyl Phosphotriester SB-1298 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= Phenethyl Phosphotriester SB-1299 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= Pyrid-4-ylethyl Phosphotriester SB-1300 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= Pyrid-4-ylmethyl Phosphotriester SB-1301 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= Imidazolylethyl Phosphotriester SB-1302 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= Cyclopropylethyl Phosphotriester SB-1303 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= Cyclopropylmethyl Phosphotriester SB-1304 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= hydroxycarbonyl- phenyltriazolylethyl Phosphotriester SB-1305 NAG26 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCXcsasg X= phenyltriazolylethyl Phosphotriester SB-1309 NAG26 AT3 46 P gsgsUuAaCaCCAuUuACUUCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1310 NAG26 AT3 45 P gsgsUuAaCaCCAuUuAcUUpCpapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1311 NAG26 AT3 45 P gsgsUuAaCaCCAuUuAcUpUpCpapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1312 NAG26 AT3 46 P gsgsUuAaCaCCAuUuACpUpUpCpapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1313 NAG26 AT3 43 P gsgsUuAaCaCCAuUUpACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1314 NAG26 AT3 44 P gsgsUuAaCaCCAUpUUpACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1315 NAG26 AT3 44 P gsgsUuAaCaCCAUUUACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1316 NAG37 AT3 25 P gsgsUuAaCaCCAuUuACpUUpCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1317 NAG37 AT3 46 P gsgsUuAaCaCCAuUuACUUCapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1318 NAG37 AT3 45 P gsgsUuAaCaCCAuUuAcUUpCpapa Homopropargyl 6 G usUsgAaGuAaAuggUgUuAaCcsasg SB-1376 NAG26 PCSK9 47 P UsusUuCuAgAcCuGuUUpUgpCUpU Homopropargyl 48 G asAsgCaAaAcAgGuCuAgAaAasGsu SB-1377 NAG26 PCSK9 47 P UsusUuCuAgAcCuGuUUpUgpCUpU Homopropargyl 48 G asAsgCaAaAcAgGuCuAgAaapasGsu SB-1378 NAG26 PCSK9 49 P CsasAgCaGaCAUuUaUCpUUpUUpU Homopropargyl 50 G asAsaAaGaUaAaugUcUgCuUgsCsu SB-1379 NAG26 PCSK9 49 P CsasAgCaGaCAUuUaUCpUUpUUpU Homopropargyl 50 G asAsaAaGaUaAaugUcUgCuUpgsCsu SB-1380 NAG26 PCSK9 51 P CsusAgAcCuGUUuUgCUpUUpUgpU Homopropargyl 52 G asCsaAaAgCaAaacAgGuCuAgsAsa SB-1381 NAG26 PCSK9 51 P CsusAgAcCuGUUuUgCUpUUpUgpU Homopropargyl 52 G asCsaAaAgCaAaacAgGuCuApgsAsa SB-1382 NAG26 PCSK9 53 P CsusAgAcCuGUUuUgCUpUUpUgpU Homopropargyl 54 G asCsaAaagCaAaacAgGucuAgsasa SB-1383 NAG26 PCSK9 53 P CsusAgAcCuGUUuUgCUpUUpUgpU Homopropargyl 55 G asCsaAaagCaAaacAgGucuapgsasa SB-1409 NAG26 TTR 56 P AsasCaGuGuUCUuGcUcUaUaATpTpTp Homopropargyl 41 G usUsaUaGaGcAagaAcAcUgUpususU SB-1445 NAG26 AT3 57 P gsgsUuAaCaCCAuUuAcUuCaaTpTpTp Homopropargyl 14 G usUsgAaGuAaAuggUgUuAaCpcsasg In Table 3, UNDERLINE = conjugation location; UPPER CASE = a 2-fluoro; lower case = 2-methoxy; aM = 2-methoxyethoxyadenosine; italics = o-(t-butyldithio)phenyl; s = phosphorothioate; Alk = 3alkyne; underlined italics = alkyne disulfide (ortho)/AlkDS-Ph; S-S = C.sub.6 Disulfide Spacer; gL = guanyl LNA; gC = cytosyl LNA; tL = thymyl LNA; aL = adenyl LNA; C3 = 3 or 5 C3-OH; p = homopropargyl phosphotriester; b = n-butylphosphotriester; h = chloroethyl phosphotriester; d = dimethylbutyl phosphotriester; Hex = cyclohexylmethyl phosphotriester; Hexe = cyclohexylethyl phosphotriester; n = 3-hexynyl phosphotriester; P = pentynyl phosphotriester; m = methylphosphonate; and B = butylphosphoramidate. The structures of these groups and of the phosphotriesters listed in Table 3 are provided in FIG. 1. A nucleoside identified by a bold, underlined letter followed by p indicates that the phosphate bonded to the 3-position of the nucleoside is the conjugation location.

Example 3. Stability in Serum

[0410] Triester containing oligonucleotide (single and double-strand) serum stability was carried out as described below.

[0411] 20 L of 250 M dsRNA stocks were made up; 4 L from each were removed and placed in 16 L of fresh mouse serum; 20 L samples were placed in PCR plates and heated on thermocycler at 37 C.; 2 L were removed at indicated time points, added to 18 L of formamide loading buffer and frozen prior to gel analysis; 2 L were loaded per well for gel analysis. Representative gel demonstrating the improved serum stability of triester containing oligonucleotides is provided in FIG. 2.

Example 4. Mouse Primary Hepatocyte Isolation and In Vitro Experiments

[0412] Primary mouse hepatocytes were isolated using the standard two-step collagenase perfusion technique (Li et. al. Methods Mol. Biol., 633:185-196; 2010). Briefly, a 6-10 week old female C57/Bl6 mouse was anesthetized by intraperitoneal injection of a mixture of ketamine (80-100 mg/kg)/xylazine (5-10 mg/kg). The abdominal cavity was then exposed and the visceral vena cava was cannulated using a 22G needle. The hepatic vein was severed and the liver was immediately perfused for 5-10 min using a solution of phosphate-buffered saline (PBS) containing 0.5 mM ETDA. This solution was immediately switched to a solution of collagenase (100 IU/mL) in Dulbecco's Modified Eagle's Medium (DMEM, Gibco) for another 5-10 min. At the end of perfusion, the liver was removed and the hepatocytes were collected in DMEM containing 10% fetal bovine serum at 4 C. The cells were then filtered through a 70 m sterile filter, washed three times in the same solution, and cell viability was assessed using Trypan Blue staining. Cells were then seeded in 96-well plates coated with 0.1% rat tail collagen or 2% matrigel and incubated for 3-4 hours at 37 C in a 5% CO.sub.2 incubator. Test compounds were then added to cells and incubated at 37 C. in a 5% CO.sub.2 incubator. At the end of the incubation period, the cells were lysed, the mRNA was isolated and the expression of the target gene was measured by qPCR and normalized to a house-keeping gene using standard protocols.

Example 5. In Vivo Experiments

[0413] Test compounds were administered to female C57Bl6 mice via either subcutaneous or intravenous (lateral tail vein) injection (200 L; 3 mice/treatment). At the appropriate time point post injection, mice were sacrificed and blood samples were collected by cardiac puncture. An approximately 50-100 mg piece of liver sample was collected and immediately frozen in liquid nitrogen. Total mRNA was isolated from liver homogenates using standard protocols, and the expression of target gene was quantified by qPCR and normalized to a house-keeping gene using standard protocols.

[0414] In another format, blood was collected from mice at different time points post dosing using sodium citrate as an anticoagulant. Plasma AT3 protein was measured using a commercially available chromogenic assay that assesses the heparin cofactor activity of AT3 using an anti-factor Xa method.

[0415] The results of these experiments are provided in FIGS. 3-15 and in Table 4.

[0416] The data in FIGS. 3-14 were obtained following administration of a single dose of the indicated hybridized polynucleotide construct at 0.5 mg/kg. The data in FIG. 15 were obtained following administration of multiple doses, designated in FIG. 15 as arrows, of the indicated hybridized polynucleotide construct at 0.25 mg/kg or at 0.125 mg/kg (designated LD in FIG. 15).

TABLE-US-00004 TABLE 4 Remaining plasma AT3 protein Compound # Day 7 (mean/SEM) Day 28 (mean/SEM) SB-0206 36.7/2.0 74.3/1.6 SB-0823 60.6/3.2 SB-0824 63.0/2.9 SB-0825 24.6/0.6 SB-0826 26.7/3.8 SB-0875 40.0/5.6 SB-0876 55.6/0.7 SB-0877 56.1/3.4 SB-0884 44.4/7.9 SB-0886 41.2/2.8 76.5/4.5 SB-0887 37.2/2.3 60.1/2.2 SB-0888 28.4/2.1 54.0/2.9 SB-0889 37.0/2.8 72.3/4.3 SB-0894 38.0/1.9 68.8/1.5 SB-0895 50.6/6.8 79.2/5.4 SB-0896 33.0/0.9 52.5/1.3 SB-0897 58.5/2.7 93.1/5.3 SB-0898 36.5/4.2 73.0/6.3 SB-0899 37.3/3.5 77.6/4.5 SB-0900 62.6/4.7 90.5/7.4 SB-0901 61.7/1.0 97.7/3.3 SB-0902 47.1/3.7 66.8/0.4 SB-0922 .sup.95/1.5 96.4/1.0 SB-0923 97.8/1.0 103.5/2.3 SB-0924 38.2/2.7 77.1/5.3 SB-0925 48.6/1.0 85.2/0.8 SB-0926 46.6/2.0 76.1/4.6 SB-0927 28.0/1.1 62.9/3.2 SB-0928 43.0/1.4 70.6/2.3 SB-0929 41.6/4.0 69.0/4.0 SB-0930 35.3/2.8 67.2/3.0 SB-0931 29.1/1.0 70.6/4.1 SB-0932 29.8/4.3 42.0/6.6 SB-0933 39.1/1.8 58.8/0.9 SB-0934 42.2/5.9 49.5/1.7 SB-0935 53.8/1.4 59.4/1.8 SB-0936 50.3/2.5 71.5/4.3 SB-0937 37.0/3.3 62.3/2.5 SB-0938 32.5/2.9 62.3/2.5 SB-0939 26.3/1.0 64.2/1.8 SB-0940 42.5/1.7 75.9/0.5 SB-0941 36.6/4.9 72.8/2.9 SB-0952 54.0/5.1 71.5/4.2 SB-0953 73.4/7.1 91.4/5.6 SB-0954 48.9/4.0 68.1/1.6 SB-0963 43.6/4.3 77.8/3.2 SB-0964 45.1/1.5 74.0/3.3 SB-0965 53.7/2.4 90.1/2.4 SB-0966 50.0/2.7 87.0/5.4 SB-0967 35.5/0.3 73.7/4.1 SB-0968 79.2/4.1 93.7/4.6 SB-0969 55.9/1.9 84.8/2.3 SB-0970 59.9/2.0 61.1/2.6 SB-0971 66.6/2.8 82.3/3.6 SB-0972 60.4/10.2 74.1/4.9 SB-0973 59.3/2.4 75.1/5.5 SB-0974 50.5/4.0 56.9/0.8 SB-0975 41.8/1.0 56.8/4.6 SB-0976 36.1/2.9 52.2/4.0 SB-0977 31.1/1.0 53.3/3.3 SB-0978 43.5/1.6 69.7/0.3 SB-0979 57.5/2.0 76.4/6.5 SB-0991 48.9/4.7 63.3/3.1 SB-0992 38.2/4.7 50.7/4.1 SB-0993 35.9/1.1 54.4/3.6 SB-0994 33.3/3.7 40.1/5.0 SB-0995 39.4/4.5 71.6/3.1 SB-0996 54.6/2.4 74.4/4.5 SB-1013 28.8/1.5 40.7/5.5 SB-1214 SB-1215 43.9/8.sup. 71.6/5.sup. SB-1216 39.9/3.sup. 66.2/2.sup. SB-1232 SB-1250 88.8/2.sup. 58.3/4.sup. SB-1251 85.5/5.sup. 60.8/5.sup. SB-1252 83.7/5.sup. 62.9/6.sup. SB-1253 79.8/1.sup. 52.6/6.sup. SB-1254 78.8/4.sup. 63.6/7.sup. SB-1255 90.1/4.sup. 43.2/2.sup. SB-1256 84.8/6.sup. 56.4/3.sup. SB-1276 SB-1277 SB-1278 SB-1279 SB-1284 SB-1285 SB-1286 SB-1289 44.0/8.sup. 67.1/10 SB-1290 44.0/5.sup. 56.5/5.sup. SB-1291 57.3/5.sup. 62.5/10 SB-1292 60.5/5.sup. 61.3/6.sup. SB-1293 44.8/3.sup. 50.6/4.sup. SB-1294 81.1/5.sup. 52.2/4.sup. SB-1295 82.5/4.sup. 64.5/2.sup. SB-1296 46.2/3.sup. 49.8/3.sup. SB-1297 39.6/4.sup. 55.8/4.sup. SB-1298 36.2/3.sup. 56.5/5.sup. SB-1299 38.4/3.sup. 59.3/5.sup. SB-1300 44.2/5.sup. 63.3/5.sup. SB-1301 51.6/6.sup. 71.5/3.sup. SB-1302 52.5/6.sup. 67.1/2.sup. SB-1303 57.5/5.sup. 84.0/4.sup. SB-1304 57.5/3.sup. 79.5/4.sup. SB-1305 67.5/3.sup. 88.6/4.sup. SB-1309 78.2/6.sup. 87.5/5.sup. SB-1310 30.9/4.sup. 47.0/6.sup. SB-1311 37.2/10 58.8/12 SB-1312 66.6/8.sup. 89.2/4.sup. SB-1313 36.9/3.sup. 47.0/3.sup. SB-1314 82.3/4.sup. 99.9/6.sup. SB-1315 82.4/2.sup. 90.7/10 SB-1316 43.4/6.sup. 63.4/4.sup. SB-1317 SB-1318 SB-1376 SB-1377 SB-1378 SB-1379 SB-1380 SB-1381 SB-1382 SB-1383 SB-1409 SB-1445 57.0/3.sup. 78.7/8.sup.

Other Embodiments

[0417] Various modifications and variations of the described invention and methods of use of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention.

[0418] Other embodiments are in the claims.